Interrelations between Dry Eye Syndrome and Tear Fluid Phospholipid Transfer Protein by Setälä, Niko
  
 
Department of Ophthalmology 
University of Helsinki 
Helsinki, Finland 
 
and 
 
National Institute for Health and Welfare 
and 
FIMM, Institute for Molecular Medicine Finland 
Biomedicum, Helsinki, Finland 
 
 
 
INTERRELATIONSHIP BETWEEN DRY EYE SYNDROME 
AND TEAR FLUID PHOSPHOLIPID TRANSFER PROTEIN 
 
 
 
Niko Setälä 
 
 
 
Academic Dissertation 
 
 
 
 
 
 
 
To be publicly discussed, 
by permission of the Medical Faculty of the University of Helsinki, 
in Auditorium Areena, Folkhälsan, Topeliuksenkatu 20, Helsinki, 
on the 29th April, 2011, at 12 noon. 
Helsinki 2011 
From the Department of Ophthalmology, University of Helsinki, Finland,  
the National Institute for Health and Welfare,  
Public Health Genomics Unit, Helsinki, Finland, and 
the Institute for Molecular Medicine Finland,  
Biomedicum, Helsinki, Finland 
 
 
 
 
Supervised by 
 
Adjunct Professor Matti Jauhiainen 
National Institute for Health and Welfare and  
Institute for Molecular Medicine Finland,  
Biomedicum, Helsinki, Finland. 
 
 
and 
 
Adjunct Professor Juha Holopainen 
Helsinki Eye Lab, Department of Ophthalmology 
University of Helsinki, Helsinki, Finland 
 
 
 
Reviewed by 
 
Professor Arto Urtti 
Faculty of Pharmacy 
University of Helsinki, Helsinki, Finland 
 
and 
 
Adjunct Professor Vesa Olkkonen 
Minerva Foundation Institute for Medical Research 
Biomedicum, Helsinki, Finland 
 
Opponent: 
 
Professor J Peter Slotte 
Department of Biochemistry and Pharmacy 
Faculty of Mathematics and Natural Sciences 
Åbo Academi 
Turku, Finland 
 
 
 
ISBN 978-952-92-8856-4 (paperback) 
ISBN 978-952-10-6929-1 (PDF, http://ethesis.helsinki.fi) 
Kopijyvä Printing House 
Jyväskylä 2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
 
 
 
4 
TABLE OF CONTENTS 
 
TABLE OF CONTENTS ............................................................................................. 4 
LIST OF ORIGINAL PUBLICATIONS .................................................................... 6 
ABBREVIATIONS ....................................................................................................... 7 
ABSTRACT ................................................................................................................... 8 
1 INTRODUCTION ................................................................................................... 10 
2 REVIEW OF THE LITERATURE ....................................................................... 11 
2.1 Tear fluid .............................................................................................................................. 11 
 2.1.1 Lipids of tear fluid ....................................................................................................... 13 
 2.1.2 Mucins of tear fluid ..................................................................................................... 15 
2.2 Dry eye syndrome ................................................................................................................ 17 
 2.2.1 Classification of dry eye syndrome ............................................................................. 19 
 2.2.2 Aqueous Tear Deficient Dry Eye ................................................................................ 20 
 2.2.3 Evaporative dry eye syndrome .................................................................................... 23 
 2.2.4 Clinical examination of dry eye ................................................................................... 25 
 2.2.5 Animal models of dry eye syndrome ........................................................................... 27 
 2.2.6 Treatment of dry eye .................................................................................................... 29 
2.3 Classification of lipids .......................................................................................................... 30 
 2.3.1 Lipoproteins and lipid transfer processes in human circulation .................................. 33 
 2.3.2 Lipid transfer proteins in lipoprotein metabolism ....................................................... 34 
 2.3.3 Characteristics of cholesterol ester transfer protein .................................................... 35 
 2.3.4 Characteristics of PLTP ............................................................................................... 35 
 2.3.5 Animal models of phospholipid transfer protein ......................................................... 37 
3 AIMS OF THE STUDY .......................................................................................... 39 
4 MATERIALS AND METHODS ............................................................................ 40 
4.1. Materials .............................................................................................................................. 40 
4.2 Methods ................................................................................................................................ 41 
 4.2.1 Tear fluid analysis ....................................................................................................... 42 
 4.2.2 Lipid monolayers ......................................................................................................... 43 
 4.2.3 Asymmetrical Flow Field-Flow Fractionation ............................................................ 43 
 4.2.4 Detection of PLTP-protein interactions ....................................................................... 44 
 4.2.5 Examination of ocular tissues ...................................................................................... 45 
 4.2.6 Experimentally induced dry eye .................................................................................. 46 
4.3 Animals ................................................................................................................................ 46 
4.4 Ethical and patient information ............................................................................................ 47 
5 RESULTS ................................................................................................................. 48 
5.1 PLTP is an active part of human tear fluid ........................................................................... 48 
 
 
 
 
5 
 5.1.1 Concentration and transfer activity of human tear fluid PLTP ................................... 48 
 5.1.2 Only the high-activity form of PLTP is present in human tears .................................. 49 
 5.1.3 Human tear fluid contains neither apolipoprotein A-I, E nor CETP ........................... 49 
5.2 Mechanism of phospholipid transfer protein –mediated lipid transfer ................................ 50 
 5.2.1 Interaction of phospholipid transfer protein with phospholipid monolayers .............. 50 
 5.2.2 PLTP is capable of transferring phospholipids from a monolayer .............................. 51 
 5.2.3 Studies of PLTP–mediated phospholipid transfer using  
         asymmetrical flow field-flow fractionation method .................................................... 52 
5.3 PLTP is secreted from the lacrimal gland ............................................................................ 53 
5.4 PLTP-protein interactions in tear fluid ................................................................................. 53 
 5.4.1 PLTP does not interact with lysozyme-C, lactoperoxidase, lipocalin, or 
         serum amyloid A ......................................................................................................... 54 
 5.4.2 PLTP forms a complex with human tear fluid mucins ................................................ 54 
 5.4.3 Characterization of the mucin–PLTP interaction ........................................................ 55 
5.5 PLTP knock-out increases dry eye symptoms in mice ........................................................ 55 
 5.5.1 PLTP is present in plasma and in tear fluid in wild-type mice .................................... 55 
 5.5.2 Corneal histology of PLTP KO mice shows dry eye changes ..................................... 55 
 5.5.3 Corneal epithelial permeability is increased in PLTP KO mice .................................. 56 
 5.5.4 PLTP KO mice have decreased expression of the tight junction protein occludin ..... 56 
 5.5.5 PLTP KO mice show normal histology of eyelids ...................................................... 56 
5.6 PLTP activity in human tears correlates to hyperosmolarity ............................................... 57 
6 DISCUSSION ........................................................................................................... 58 
6.1 PLTP is a component of normal tear fluid ........................................................................... 58 
6.2 PLTP is secreted from the lacrimal gland ............................................................................ 58 
6.3 CETP and human tear fluid .................................................................................................. 59 
6.4 PLTP activity in tear fluid .................................................................................................... 59 
6.5 PLTP activity and apolipoproteins in tear fluid ................................................................... 60 
6.6 PLTP-protein interactions in tear fluid ................................................................................. 61 
6.7 PLTP in an air-water environment ....................................................................................... 61 
6.8 PLTP and mucins in tear fluid .............................................................................................. 62 
6.9 PLTP and phospholipid transfer mechanism ....................................................................... 63 
6.10 PLTP–deficient mice and dry eye ...................................................................................... 64 
6.11 PLTP as a scavenger of the ocular surface ......................................................................... 65 
7 SUMMARY AND CONCLUSIONS ...................................................................... 67 
8 ACKNOWLEDGEMENTS .................................................................................... 69 
9 REFERENCES ......................................................................................................... 70 
 
 
 
 
 
6 
LIST OF ORIGINAL PUBLICATIONS 
 
This dissertation is based on the following original publications, which are 
referred to in the text by Roman numerals I–IV: 
 
 
 
 
I. Jauhiainen M, Setälä N, Ehnholm C, Metso J, Tervo T, Eriksson O, 
Holopainen JM. Phospholipid transfer protein is present in human tear 
fluid. Biochemistry. 2005;44:8111-6. 
 
 
II. Setälä NL, Holopainen JM, Metso J, Wiedmer SK, Yohannes G, 
Kinnunen PK, Ehnholm C, Jauhiainen M. Interfacial and lipid transfer 
properties of human phospholipid transfer protein: implications for the 
transfer mechanism of phospholipids. Biochemistry. 2007;46:1312-9. 
 
 
III. Setälä NL, Holopainen JM, Metso J, Yohannes G, Hiidenhovi J, 
Andersson LC, Eriksson O, Robciuc A, and Jauhiainen M. Interaction 
of Phospholipid transfer protein with human tear fluid mucins. J Lipid 
Res. 2010;51:3126-34. 
 
IV. Setälä NL, Metso J, Jauhiainen M, Sajantila A, Holopainen JM. Dry 
eye symptoms are increased in mice deficient in phospholipid transfer 
protein. In press Am J Pathol. 
 
 
 
These publications have been reproduced with the kind permission of their 
copyright holders.
 
  
 
 
 
7 
ABBREVIATIONS 
 
apoA, apoE Apolipoproteins A and E 
AsFlFFF  Asymmetrical flow field-­‐flow fractionation 
BSM Bovine submaxillary mucin 
CETP Cholesteryl ester transfer protein 
CF Carboxyfluorescein 
CPM Counts per minute 
DES Dry eye syndrome 
DPPC Dipalmitoylphosphatidylcholine 
EIDE Experimentally induced dry eye 
HA-PLTP High-activity phospholipid transfer protein 
HDL  High-density lipoprotein 
Ig Immunoglobulin 
KCS Keratoconjunctivitis sicca 
KO Knockout 
LA-PLTP Low-activity phospholipid transfer protein 
MGD Meibomian gland dysfunction 
MMP Matrix metalloproteinase 
MUC Mucin 
PBS Phosphate buffered saline 
PC Phosphatidylcholine 
PL  Phospholipid 
PLTP Phospholipid transfer protein 
POPC Palmitoyl-oleoyl phosphatidylcholine 
SE Standard error of the mean 
Sec Seconds 
SEC Size-exclusion chromatography 
SUV Small unilamellar vesicle 
TBUT? Tear break-up time 
TF Tear Fluid 
Tlc Human tear lipocalin 
WT Wild-type 
π Surface pressure 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
8 
ABSTRACT 
 
Background and aims: The simplified model of human tear fluid (TF) is a three-
layered structure composed of a homogenous gel-like layer of hydrated mucins, an 
aqueous phase, and a lipid-rich outermost layer found in the tear-air interface. The 
precise composition of the superficial lipid layer remains unknown It is assumed that 
amphiphilic phospholipids are found adjacent to the aqueous-mucin layer and 
externally to this a layer composed of non-polar lipids, such as cholesteryl esters and 
triglycerides, face the tear-air interface. The lipid layer prevents evaporation of the TF 
and protects the eye, but excess accumulation of lipids may lead to drying of the 
corneal epithelium. Thus the lipid layer must be controlled and maintained by some 
molecular mechanisms. In the circulation, phospholipid transfer protein (PLTP) and 
cholesteryl ester transfer protein (CETP) mediate lipid transfers. The aim of this 
thesis was to investigate the presence, molecular mechanisms and interactions 
of lipid transfer proteins in human TF. The purpose was also to study the tole 
of these proteins in the development of dry eye syndrome. 
 
Methods: TF samples were collected with microcapillaries. The presence of TF 
PLTP and CETP was studied by western blotting and mass spectrometry. The 
concentration of these proteins was determined by ELISA. The activities of the 
enzymes were determined by specific lipid transfer assays. To study the molecular 
mechanisms involved in PLTP mediated lipid transfer Langmuir monolayers and 
asymmetrical flow field-flow fractionation (AsFlFFF) was used.   The AsFlFFF 
method was also used to determine the sizes of these molecular assemblies. Ocular 
tissue samples were stained with monoclonal antibodies against PLTP to study the 
secretion route of PLTP. Heparin-Sepharose affinity chromatography was used for 
PLTP pull-down experiments and co-eluted proteins were identified with MALDI-
TOF mass spectrometry or Western blot analysis. To study whether PLTP plays any 
functional role in TF PLTP-deficient and experimentally induced dry eye (EIDE) mice 
were examined. The activity of PLTP was studied in dry eye patients. 
 
Results: PLTP is a component of normal human TF, whereas CETP is not. Also the TF 
of wild-type mice displayed immunoreactivity against PLTP. In human TF PLTP 
concentration was about 2-fold higher than that in human plasma. PLTP-facilitated 
phospholipid transfer activity in TF was also significantly higher than that measured in 
plasma. Inactivation of PLTP by heat treatment or immunoinhibition abolished the 
phospholipid transfer activity in tear fluid. PLTP was found to be secreted from lacrimal 
glands. PLTP seems to be surface active and is capable of accepting lipid molecules 
without the presence of lipid-protein complexes. The active movement of 
radioactively labeled lipids and high activity form of PLTP to acceptor particles 
suggested a shuttle model of PLTP-mediated lipid transfer. In this model, PLTP 
physically transports lipids between the donor and acceptor. The particle diameter of 
PLTP was 6 nm as determined by AsFlFFF analysis. MALDI-TOF analysis of 
Heparin-Sepharose fractions identified several candidate proteins, but protein-protein 
interaction assays revealed only ocular mucins as PLTP interaction partners in TF. In 
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mice with a full deficiency of functional PLTP enhanced corneal epithelial damage, 
increased corneal permeability to carboxyfluorescein, and decreased corneal epithelial 
occludin expression was demonstrated. These pathological signs were worsened by 
EIDE both in wild-type and PLTP knock-out mice. Increased tear fluid PLTP activity 
was observed among human DES patients. 
 
Conclusions: These results together suggest a scavenger property of TF PLTP: if the 
corneal epithelium is contaminated by hydrophobic material, PLTP could remove 
them and transport them to the superficial layer of the TF or, alternatively, abolish 
lipphilic substances by binding them and transporting them through the naso-lacrimal 
duct. Thus, PLTP might play an integral role in tear lipid trafficking and in the 
protection of the corneal epithelium. The increased PLTP activity in human DES 
patients suggests an ocular surface protective role for this lipid transfer protein. 
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1 INTRODUCTION 
Dry eye syndrome (DES) is a common external eye disease that arises from a wide 
variety of etiologies. The prevalence of dry eye ranges from 5% to 30% in people 
aged over 50 years. Dryness, redness, foreign body sensation, and burning and itching 
of the eyes are typical symptoms of dry eye. Somewhat controversially, intermittent 
excessive tearing can also be the main symptom of irritated eye. These symptoms are 
often unpleasant; moderate cases may affect quality of sight and life, but severe cases 
may lead to the damage of the ocular surface, resulting in impaired vision or even 
perforation of the eye. 
The underlying biochemical mechanisms in the development of DES and the precise 
composition of human tear fluid are only partially known. The tear film is a complex 
three-dimensional gel-like aqueous fluid composed of a complex mixture of 
hydrocarbons, proteins, and lipids. The outermost structure of the tear fluid, the lipid 
layer, is composed of wax esters, sterol esters, and polar lipids. Based on the 
hydrophobic effect previously identified, it has been suggested that in the tear fluid, 
the polar phospholipids are disposed adjacent to the aqueous-mucin layer and 
externally to this is a layer composed of non-polar lipids, such as cholesteryl esters 
and triglycerides, facing the tear-air interface. This type of organization of lipids 
opposes evaporation, but the ocular surface epithelium and mucin components become 
vulnerable to lipid contamination. Excess lipidation of the ocular surface would lead 
to increased dewetting of the corneal epithelium and the development of DES. A 
mechanism is needed to organize and maintain the homeostasis of the lipid layer and 
to prevent epithelial or mucin contamination. 
 
Phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) 
have an important role in plasma lipoprotein metabolism. PLTP is a glycoprotein that 
was originally identified from plasma based on its capability to transfer phospholipids 
between phospholipid vesicles and high-density lipoprotein (HDL). In this study the 
possible role of PLTP in maintaining the delicate lipid homeostasis in the tear fluid is 
explored. 
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2 REVIEW OF THE LITERATURE 
2.1 Tear fluid 
Tear fluid (TF) covers the entire ocular surface and serves multiple purposes, 
including a barrier function, lubrication, nutrition, and antimicrobial protection. Good 
visual acuity is also dependent on normal TF because it provides a smoother ocular 
surface, which is important for the optical properties of the eye (Bron et al., 2004; 
Goto et al., 2006). 
 
The “three layer theory” proposed by Wolff (1946) has stood as a standard model for 
the composition of tear fluid for a long time. This model describes the tear fluid as 
three separate layers: the superficial lipid layer from Meibomian secretion; the middle 
aqueous layer, which is the main component, secreted by the lacrimal gland and the 
accessory glands of Krause and Wolfring; and the deepest mucin layer secreted by 
goblet cells of the conjunctiva. The trilayered model is based on observations of ocular 
surface sections and findings from slitlamp attached to a microscope. However, recent 
studies with more highly developed equipment have questioned this model and 
described TF as having a more homogeneous structure, without separate aqueous and 
mucin layers (Chen et al., 1997; Butovich, 2008). It is easy to imagine that TF does 
not stand as a stable structure. Continuous movement of the eyelid and blinking, 
secretion of new meibum, aqueous, and mucin, tear evaporation and drainage to the 
nasal ducts keep these dynamic structures in constant movement. The structure of TF 
lipids and mucins are reviewed below in detail (see 2.2.1 and 2.2.2). 
 
The production of tears is divided into basal, reflex, and emotional tearing. The 
volume of basal TF is estimated to be around 7 µl (Scherz et al., 1974; Tiffany, 1994), 
where around 1 µl covers the ocular surface and the rest is situated on the marginal 
meniscuses. The turnover rate of TF is 24.0 +/- 14.2 %/min (Shimizu et al., 1993), and 
basal tear secretion produces 2–3 ml in a day, calculated from dye dilution tests and 
from corneal epithelial cell desquamation (Ehlers et al., 1972). The thickness of TF 
ranges from 3 to 45 µm depending on the investigative method, while the most novel 
interferometry and optical coherence tomography measurements indicate that values 
around 3–4 µm seem to be more accurate (Prydal et al., 1992; King-Smith et al., 2000; 
Bron et al., 2004). Thickness of TF is highest after each blink, after which it starts to 
decrease. The tear evaporation rate is estimated to be 15.6 +/- 3.8 x 10(-7) g/cm2 per 
second (Tsubota and Yamada, 1992). TF stability has been associated with a high 
surface pressure (low surface tension), which is due to both TF lipids and proteins. 
The average TF surface tension is around 70 mN/m (Glasgow et al., 2010). During 
sleep, secretion of all major proteins and water is inhibited, but the release of 
immunoglobulin A (IgA) continues (Tan et al., 1993).  
 
In the basal TF, the principal electrolytes are Na+, K+, Cl-, and HCO-, with lower 
levels of Mg2+ and Ca2+. Tears are isotonic with serum, although the proportions of 
ions are slightly different and especially the concentration of tear potassium (K+) is 
higher (Gilbard, 1994). Small molecules that occur in serum are found in TF; these 
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include glucose, lactate, urea, etc., but at different levels. The mean pH of basal TF is 
7.0, ranging from 6.5 to 7.6 (Abelson et al., 1981), and the TF’s osmolarity is 303 to 
349 mOsm (Tomlinson et al., 2006). Many conditions, such as infection, dryness, and 
the neural control of lacrimal glands, change these proportions of the TF components. 
Typically, this is seen in rapid reflex tearing, where a substance irritating the cornea 
launches water secretion and dilution, or in slower changes like in dry eye syndrome, 
where the rise of TF osmolarity is a key element. 
 
Proteins in TF have numerous functions, including bacterial defense, wetting by 
lowering surface tension, transport, wound healing, and the regulation of 
inflammatory processes. In basal TF, total protein quantity is around 20 g/L (Dohlman 
et al., 1976). The protein composition of tear film has been recently studied using 
mass spectrometric techniques. Li et al. (2005) identified 54 proteins and Zhou et al. 
(2009) counted 93 proteins, while 491 proteins were identified by de Souza et al. 
(2006) and our unpublished data identified around 250 proteins (Rantamäki et al., 
unpublished data). These last two results seem to be overestimates, as the TF 
proteome contains several intracellular proteins. The four major proteins—lysozyme, 
lactoferrin, lipocalin, and IgA—are secreted into TF from the ductal epithelium of the 
lacrimal gland and associated plasma cells.  
Lysozyme damages bacterial cell walls by hydrolyzing 1,4-beta-linkages between N-
acetylmuramic acid and N-acetylglucosamine (Van Haeringen, 1981); lactoferrin 
binds ion iron (Fe III) away from microbial metabolism (Broekhuyse, 1975); and IgA 
has antibody specificity to various pathogens (Franklin, 1989). These are all part of 
ocular immune defense. 
Tear lipocalin (Tlc), firstly called tear prealbumin by Erickson due to its properties in 
electrophoresis, was characterized from TF in 1956. Tlc comprises 15–33% of all 
proteins in TF. It is supposed to act as a general scavenger of TF because it has 
endogenous ligands for lipophilic substances from different chemical classes, 
including phospholipids, fatty acids, fatty alcohols, and glycolipids (Glasgow et al., 
1995). Recently, Tlc’s ability to remove fluorescently labeled lipids from the surface 
of the cornea has been shown (Glasgow et al., 2010), even though it seems that Tlc 
does not possess any neutral or polar lipid transfer activity between lipid vesicles 
(Saaren-Seppala et al., 2005). Tlc also binds microbial siderophores with high 
affinities. The role of Tlc in innate immunity is discussed, while the addition of 
exogenous Tlc could inhibit bacterial and fungal growth under iron-limiting conditions 
(Fluckinger et al., 2004). In addition to TF, Tlc is also expressed in von Ebner’s gland, 
the prostate, trachea, and nasal mucosa (Redl, 2000). 
 
Various other substances like inflammatory mediators (interleukin-1 (IL-1), tissue 
necrosis factor alpha (TNF-α), matrix metalloproteinase-9 (MMP-9), growth factors 
(epidermal growth factor (EGF), transforming growth factor beta (TGF-β), hepatocyte 
growth factor (HGF), and remodeling enzymes (collagenase, plasmin, plasminogen 
activator) have been detected in tears in various disorders relative to normal controls. 
TF also contains corneal and conjunctival epithelial cells and white blood cells, which 
increase in number during inflammation (Tiffany, 2003).  
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Irritation of the ocular surface, and especially the cornea, results in reflex tearing, 
which is under the control of the parasympathetic nervous system. The mechanical 
corneal stimulus causes tearing more easily than chemical stimuli, and the central 
cornea is more sensitive than the periphery (Situ and Simpson, 2010). Ocular stimulus 
that causes discomfort and/or pain stimulates the sensorial endings of the nervus 
trigeminus, which results in a signal being given to the lacrimal glands, leading to 
their reflex hypersecretion. In addition, an irritation of the non-ocular area of the first 
branch of the trigeminus that innervates the nasal mucosa leads to reflex tearing. The 
Schirmer II test is used to measure reflex tearing related to nasal irritation. The 
purpose of reflex hypersecretion is to wash out foreign material and post-irritative 
secretions. Damage to nerves or the chemical blockade of the parasympathetic 
stimulus with cocaine or atropine diminishes reflex tearing.	  
 
Emotional tears are secreted due to emotional stimulus like sorrow, suffering, physical 
pain, and sometimes even happiness. Emotional tears contain more protein-based 
hormones such as prolactin, adrenocorticotropic hormone, and leucine enkephalin, 
than do basal or reflex tears (Sullivan, 2004). The limbic system, specifically the 
hypothalamus, which is involved in emotional control, also has a degree of control 
over the autonomic system. The parasympathetic branch of the autonomic system 
controls the lacrimal glands via the neurotransmitter acetylcholine through nicotinic 
and muscarinic receptors. When these receptors are activated, the lacrimal gland is 
stimulated to produce tears. Thus, as basal tears are the result of a spontaneous 
neuroglandular activity, and reflex tears are the result of an external sensorial 
stimulation, emotional tears are the result of a cognitive and emotional brain process. 
Most mammals produce tears in response to severe pain stimulus, but crying as an 
emotional phenomenon is considered to be uniquely human, possibly due to advanced 
self-awareness. However, some studies suggest that elephants, gorillas, and camels 
may cry. 
 
2.1.1 Lipids of tear fluid 
Meibomian glands, described in 1666 by the German physician Heinrich Meibom, are 
sebaceous glands that are located at the margins of the upper and lower eyelids of 
humans and mammals. These glands produce a lipid-rich secretion, also called 
meibum (Nicolaides et al., 1981), which is constantly released from the orifices of the 
glands. As lipids are less dense than water and due to the hydrophobic effect, they rise 
on the surface of the aqueous subphase, forming the lipid-enriched outermost layer of 
TF (McCulley and Shine, 1997). The lipid layer plays an important role in reducing 
the evaporation rate of the tear film and stabilizing it (Holly, 1973). It is also noted 
that protein adsorption at the air-water interface could be associated with structural 
changes. In the experimental tear model presented by Miano et al. (2005), the 
enzymatic activity of lysozyme is maintained in the presence of an outermost 
Meibomian lipid layer that prevents denaturation, while exposure at the air-aqueous 
interface induces significant lysozyme degradation. Thus, the TF lipid layer seems to 
be important in maintaining tear enzyme activity. 
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The Meibomian gland is a prominent source of lipids for the tear film, and originally 
the samples to study TF lipids were collected directly from Meibomian gland 
secretions (Nicolaides et al., 1981). However, it would have been a mistake to exclude 
other likely sources of lipids, such as the conjunctiva, cornea, and lipids secreted from 
palpebral skin (Butovich, 2008). Another problem in TF lipid research has been that 
former experimental techniques include sample hydrolysis and transesterification to 
achieve simpler structures before analysis. With this technique, the lipid compounds 
have been characterized only in lipid classes, and it has been difficult to resolve the 
correct complex lipid composition from the mosaic fragments. This is important, as 
even a little variation in a chemical structure of a lipid compound leads to changes in 
the properties and physiological activity of the molecule (Butovich, 2009). 	  
At present, the proposed arrangement of the TF lipid layer is described as a bilayered 
structure and, based on its hydrophobic effect, it has been suggested that the polar 
phospholipids are disposed adjacent to the aqueous-mucin layer. Externally to this, a 
layer composed of non-polar lipids such as cholesteryl esters and triglycerides faces 
the tear-air interface (McCulley and Shine, 1997; Greiner et al., 1996; Kulovesi et al., 
2010).  	  
The mechanism that controls and organizes the tear lipid layer is important. If 
aqueous-mucin layer becomes thin enough, the lipids can contaminate the ocular 
surface. This would lead to dewetting and drying of the corneal epithelium. 
Furthermore, some lipids, including fatty acids, are known to induce apoptosis in a 
variety of epithelia (Malhi et al., 2006; Said et al., 2007). 
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Figure 1. Proposed model of tear film (Bron et al., 2004) and tear film lipid layer 
                 (McCulley and Ward, 2001). 
 
2.1.2 Mucins of tear fluid 
Mucins are a family of high molecular weight (0.5 to 20 MDa) and heavily O-
glycosylated proteins produced by epithelial cells. In addition to the human ocular 
surface, mucins are found in the respiratory, gastrointestinal, and urogenital tracts, and 
the middle ear epithelium. Mucin molecules can be divided into two subfamilies: the 
secreted mucins and membrane-bound mucins. Characteristic of the mucin molecules 
are serine, threonine, and proline–rich tandem repeats (STP-repeats) of amino acids in 
their protein backbone (Bansil and Turner, 2006). These STP-repeats are the sites for 
O-glycosylation, where branched oligosaccharide chains consisting of 5–15 monomers 
are attached to the protein core and arranged in a “bottle brush” configuration 
(Gendler and Spicer, 1995). Mucins have a considerable capacity to tie up water and 
the high glycosylation makes them resistant to proteolysis. Between the STP-repeats 
of secreted mucins lie regions with a high proportion of cysteine. These sites have 
been shown to be involved in the dimerization of two mucin molecules via disulfide 
bond formation, as well as the subsequent polymerization of the dimers to form 
multimers (Sheehan et al., 2004).	  Through polymerization, secreted mucin molecules 
form a complex, gel-like adherent mucus that lubricates, hydrates, and serves as a 
barrier to pathogens. Atomic force microscopy studies of ocular mucin show that most 
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of the mucin fibers are between 200 and 600 nm long (Round et al., 2002), while 
fibers up to 2 µm have been observed in pig gastric mucin (Deacon et al., 2000). 
 
At least 19 human mucin genes have been distinguished by cDNA cloning. The mucin 
genes show a high variation. While each mucin gene has its own tandem repeat amino 
acid sequence and its alleles vary in number, wide polymorphisms are found within 
and among individuals (Perez-Vilar and Hill, 1999). In the literature, the abbreviation 
for human mucins is MUC, while Muc refers to mice mucins and rMuc to rat-derived 
mucins. Several analogs to human mucins are found in animals, such as in Bovine 
submaxillary mucin (BSM), which is widely used in experimental procedures. 
 
The mucins of the ocular surface are secreted by conjunctival goblet cells and the 
apical cells of the stratified conjunctival and corneal epithelia (Gipson et al., 2003). 
Like all mucins, the ocular mucins can be divided into secreted mucins (MUCs 2, 
5AC, and 7) and membrane-bound mucins (MUCs 1, 4, 15, 16, and 20) (Gipson et al., 
2010). The secreted mucins of TF are stored as polymers but secreted as monomers. 
The lower detected molecular weight of TF mucins indicates that the mucins do not 
form large polymers on the TF, perhaps preventing the formation of viscous mucus 
that could induce light scatter within the tear film (Spurr-Michaud et al., 2007). 
 
MUC5AC is the major secreted mucin in human TF. In human TF, MUC2 is only 
detected at low levels by polymerase chain reaction (PCR) and the immunoblotting of 
tears. MUC7 is a small soluble mucin, which does not have cysteine-rich domains and 
is found as a monomer in TF. MUC7 has been shown to have antifungal and 
antimicrobial activity (Situ et al., 2003). 
 
The epithelial surfaces of the cornea and conjunctiva serve as a border between the 
epithelial layer and TF. The surfaces of these tissues consist of many tiny membrane 
folds called microplicae. Membrane-bound mucins, which are smaller in molecular 
weight than the polymeric secreted mucins, are situated at the apices of the 
microplicae to form a structure known as the glycocalyx (Gipson, 2004). MUC1 and 
MUC16 are present on both corneal and conjunctival epithelia, while MUC4 is most 
prevalent in the conjunctival epithelium. These membrane-bound mucins are 
transmembrane proteins that have a short cytoplasmic tail, a transmembrane domain, 
an autoproteolytic domain called the SEA region, and an extracellular region that 
forms the glycocalyx. The glycocalyx layer can extend up to 500 nm from the 
epithelial surface (Hilkens et al., 1992). Data from freeze-fracture experiments of gut 
epithelium and mouse TF indicate that these mucins form rod-like extensions from the 
surface membrane (Chen et al., 1997). The extracellular parts of membrane-bound 
mucins are released from the SEA regions into the tear film and these ectodomains 
constitute a component of aqueous tear fluid. Recent data from yeast studies have 
shown that the mucin-like transmembrane proteins can activate a signaling pathway in 
response to increased osmolarity (Tatebayashi et al., 2007). Thus, it is hypothesized 
that membrane-bound mucins could have a sensory function in relation to the 
extracellular environment. 
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2.2 Dry eye syndrome 
DES is the most common ocular problem. It was defined by the International Dry Eye 
WorkShop (2007) as a: multifactorial disease of the tears and ocular surface that 
results in symptoms of discomfort, visual disturbance,	   and tear film instability with 
potential damage to the ocular surface. It is accompanied by increased osmolarity of 
the tear film	  and inflammation of the ocular surface. 
 
In population studies (i.e., the Salisbury Eye Evaluation, the Beaver Dam Eye Study, 
the Melbourne Visual Impairment Project, Blue Mountains, and the Women’s Health 
Study) the prevalence of dry eye ranges from 5% to 30% in people aged over 50 years 
(Schein et al., 1997; Moss et al., 2000; McCarty et al., 1998; Chia et al., 2003; 
Schaumberg et al., 2003). The prevalence of moderate-to-severe dry eye is closer to 
the lower estimate of the range, whereas the prevalence of mild dry eyes lies closer to 
the higher estimate of the range. The requirement of symptoms in the definition of dry 
eye is noteworthy, as tens of millions of people have mild dry eyes that may be 
notable only when some adverse extrinsic factor is present, such as low humidity or 
contact lens (CL) wear. Thus, most people with mild dry eye are unaware that their 
ocular symptoms belong to a dry eye syndrome. Dryness, redness, foreign body 
sensation, burning and itching of the eyes are the most common symptoms of dry eye. 
Usually, both eyes are affected and unpleasant sensations seem to get worse as the day 
goes on, during work, and in dry air conditions.  	  
 
TF instability and hyperosmolarity are core mechanisms of dry eye (Figure 2). Tear 
film hyperosmolarity causes hyperosmolarity of the ocular surface epithelial cells and 
stimulates a cascade of inflammatory events involving mitogen-activated protein 
(MAP) kinases and nuclear factor kappa B (NFkB) signaling pathways (Li et al., 
2004) and the generation of inflammatory cytokines (interleukin-1), tumor necrosis 
factor alpha (TNF-α), and matrix metalloproteinases (MMP-9). In addition, altered 
concentrations of lysozyme and lactoferrin have been detected in the tears of DES 
patients (Stuchell et al., 1981). 
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              Figure 2. Tear Hyperosmolarity in the development of dry eye syndrome. 
 
 
DES has several different etiologies and several forms of appearance; thus, it has been 
described with several different terms. Keratoconjunctivitis sicca (KCS), a Latin term 
referring to dryness and inflammation of the cornea and conjuctiva, was first described 
by Swedish ophthalmologist Henrik Sjögren (1933). Nowadays, KCS is commonly 
used interchangeably with DES, whereas an autoimmune-mediated disease of the 
lacrimal and salivary glands, Sjögren syndrome, is named after Doctor Sjögren.  
Xerophthalmia (the Greek term Xeros meaning dry) is a bilateral ocular disease caused 
by Vitamin A deficiency. It is characterized by night blindness, dryness of the ocular 
surface, and keratomalacia, softening and malformation of the cornea. The Delphi 
group (Behrens et al., 2006) has proposed to use the term dysfunctional tear syndrome 
(DTS) as a replacement for the term dry eye, to better describe the underlying failure 
in wetting of the ocular surface. 
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2.2.1 Classification of dry eye syndrome 
Over time, new knowledge and diagnostic possibilities have changed the picture, as 
well as the classification, of DES. First, only the most severe cases of dry eye were 
documented. Thereafter, the Sjögren syndrome type of dry eye was described. The 
contemporary high requirements of sight and the knowledge of the pathogenesis of dry 
eye have led to the establishment of several classifications of DES for different 
diagnostic, clinical, or treatment purposes.  
The National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye (Lemp et 
al., 1995) was the first major consensus committee to describe DES. However, the 
classification in its report does not reflect newer knowledge about pathophysiological 
mechanisms, effects on vision, or the utility of an assessment of the severity of the 
disease. 
The triple classification of dry eye for practical clinical use (Murube et al., 2005) is 
combined from reports presented at the 14th Congress of the European Society of 
Ophthalmology. It represents dry eye in relation to three separate schemes: one based 
on etiopathogenesis; one based on the glands and tissues targeted in dry eye; and one 
based on disease severity. However, the evidence-based referencing of this 
classification has been found to be limited (Lemp et al., 2007). 
The Delphi panel (Behrens et al., 2006) proposed to change the name dry eye 
syndrome, although embedded in the literature, to dysfunctional tear syndrome, which 
more accurately describes the pathophysiological events in dry eye. The Delphi panel 
neglected to state whether lid disease is present or absent in particular cases of dry 
eye, as it is frequently difficult to identify these two forms of ocular surface disease. 
 
DEWS (Lemp et al., 2007) presented the most recent classification of the 
epidemiology, pathogenesis, clinical manifestation, and possible therapy of DES. It 
gathered knowledge from previous classifications and research knowledge existing at 
the time. The two major classes of DES, aqueous tear-deficient dry eye (ADDE) and 
evaporative dry eye (EDE), were introduced. ADDE refers to a failure of lacrimal tear 
secretion, while EDE is constituted of intrinsic or extrinsic causes that lead to the 
evaporation of the tear film. The DEWS type classification of DES is presented in 
Figure 3 and below in detail. 
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Figure 3. Classification of dry eye syndrome (DEWS, 2007). 
 
 
2.2.2 Aqueous Tear Deficient Dry Eye 
ADDE entails that the eye is dry due to diminished lacrimal tear secretion. The 
different forms of aqueous DES are listed here according to the DEWS 
recommendation. 	  
I. Sjögren syndrome dry eye 
Primary Sjögren syndrome is defined as an autoimmune disease of the exocrine 
glands, characterized by lymphocytic infiltration to the lacrimal and salivary glands 
and multiple sites of the epithelia. Inflammatory activation within the glands leads to 
the expression of alpha-fodrin and Ro/La ribonucleoprotein complex autoantigens at 
the surface of epithelial cells (Nakamura et al., 2006). The lacrimal glands are 
infiltrated by activated CD4+ and CD8+ T-cells (Hayashi et al., 2003). Inflammation in 
the lacrimal glands causes acinar and ductular cell death and the hyposecretion of 
tears. Hyposecretion of TF is enhanced by a neurosecretory block, due to the effects of 
locally released and circulating inflammatory antimuscarinic antibodies (anti-3 
antibody) directed against muscarinic receptors within the glands (Dawson et al., 
2005). In Sjögren syndrome, the antibodies to nuclear Ro(SSA) or La(SSB) antigens 
are present in the serum. The total prevalence of Sjögren syndrome is estimated to 
range between 3 to 4%, while the manifestation of Sjögren syndrome varies from very 
mild irritation to severe dry eye; furthermore, no all of the patients are aware of their 
diagnosis.  
 
Secondary Sjögren syndrome consists of the features of primary Sjögren syndrome 
together with the features of another autoimmune disease, such as rheumatoid arthritis, 
systemic lupus erythematosus, polyarteritis nodosa, Wegener’s granulomatosis, 
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systemic sclerosis, primary biliary sclerosis, or mixed connective tissue disease (Fries 
et al., 1994). The precise origin of autoimmune damage to acinar cells is not known, 
but risk factors including genetic profile (Moutsopoulos and Manoussakis, 1989), low 
androgen hormone status (Porola et al., 2007), and a nutritional deficiency in omega-3 
fatty acids and vitamin C has been reported (Cermak et al., 2003). One proposed 
mechanism for the accumulation of autoimmune cells in the lacrimal glands is an 
interferon system activation launched by a previous viral infection. In addition, 
environmental factors leading to increased evaporation may act as a trigger by 
invoking inflammatory events at the ocular surface through a hyperosmolar 
mechanism (Figure 2). 
 
II. Non-Sjögren syndrome dry eye 
Non-Sjögren syndrome dry eye is a form of tear-deficient dry eye due to lacrimal 
dysfunction, where a systemic autoimmune features characteristic of Sjögren 
syndrome has been excluded. Causes of lacrimal dysfunction are divided into primary, 
congenital, secondary obstructive, and neurological forms.  	  
IIa. Primary lacrimal gland deficiencies 
Aging is the main reason for lacrimal gland dysfunction. According to population 
studies, the incidence of DES increases with age, although in the literature different 
aspects of normal tear secretion volume in elderly people have been postulated 
(Mathers et al., 1996 and Damato et al., 1984). In a study of lacrimal gland histology 
from elderly people, the majority of samples showed an increase in periductal fibrosis, 
interacinar fibrosis, paraductal blood vessel loss, and acinar cell atrophy (Obata et al., 
1995). The aging of the population in Western countries will increase the prevalence 
of DES in the near future.	  	  
Alacrima is a rare congenital cause of lacrimal secretory disorders (Davidoff and 
Friedman, 1977). It is caused by mutations in the AAAS gene on chromosome band 
12q13. The affected gene encodes the alacrima-achalasia-adrenal insufficiency-
neurologic (ALADIN) protein disorder, which plays a role in RNA and/or protein 
trafficking to regulate intracellular protein transport (Sarathi and Shah, 2010). 
Symptoms include a selective absence of tearing in response to emotional stimulation, 
but a normal secretory response to mechanical stimulation.	  
 
Familial dysautonomia (Riley Day syndrome) is an autosomal recessive disorder 
where lacrimal dysfunction is a major feature (Riley et al., 1949). It is caused by a 
splicing mutations on chromosome 9(q31) in the gene encoding an IkappaB kinase-
associated protein (Slaugenhaupt et al., 2001). A developmental and progressive 
neuronal abnormality of the parasympathetic innervations of the lacrimal gland and a 
defective sensory innervation of the ocular surface, which affects both small 
myelinated and unmyelinated trigeminal neurons, has been found. A generalized 
insensitivity to pain is accompanied by a lack of both emotional and reflex tearing. 
There is a unique pattern of serum catechols with high norepinephrine and low 
dopamine levels, and during physical and emotional stress, autonomic crises may 
develop. 
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IIb. Secondary lacrimal gland deficiencies 
Lacrimal gland infiltration due to systemic disease can reduce the secretion of tear 
fluid. In sarcoidosis, infiltration of the lacrimal gland by sarcoid granulomata 
(Prabhakaran et al., 2007); in lymphoma, the lymphomatous cells (McKelvie, 2010); 
and in AIDS, the infiltration of T-cells may cause the development of DES. In AIDS-
related dry eye, there seems to be a predominance of CD8 suppressor cells, while CD4 
helper cells are dominant in Sjögren syndrome (Itescu et al., 1989). In graft versus 
host disease, a colocalization of transplanted periductal T-lymphocytes (CD4 and 
CD8) with antigen-presenting fibroblasts cause fibrosis of the lacrimal glands and dry 
eye symptoms that typically occur six months after hematopoietic stem cell 
transplantation (Tabbara et al., 2009). 
Lacrimal gland ablation can occur due to trauma, or sometimes is unavoidable in 
tumor surgery. Structurally, the ducts from the main lacrimal gland pass through the 
palpebral part; thus, failed lid surgery can be expected to have the same effect as 
excision of the main gland. DES can be caused by partial or complete ablation of the 
lacrimal gland, but is not an obligatory consequence of this, presumably because 
accessory gland and conjunctival secretion may be enough to compensate for the 
secretion (Scherz and Dohlman, 1975). 
Lacrimal gland denervation can cause DES, particularly when the compensative 
accessory glands are innervated and under similar reflex to the main lacrimal gland 
(Seifert et al., 1997).  	  
IIc. Obstruction of the lacrimal gland ducts 
Obstruction of the ducts of the main and accessory lacrimal glands, caused by 
different forms of cicatrizing conjunctivitis, leads to aqueous-deficient dry eye. The 
picture of obstructive Meibomian gland dysfunction (MGD) is common, and 
deformation of the palpebral aperture hinders the spreading of the tear fluid. 
Trachoma caused by Chlamydia trachomatis is a globally vast cause of blindness, 
where corneal opacity is caused by a trichiasis and a cicatrizing Meibomian gland 
obstruction. Dry eye is very common, resulting from lacrimal duct obstruction and lid 
malapposition (Guzey et al., 2000). 
Dry eye due to lacrimal obstruction, cicatricial MGD, poor lid apposition, and notable 
conjunctival scarring, is seen in cicatricial and mucous membrane pemphigoid (a 
mucocutaneous disorder characterized by blistering of the skin and mucous 
membranes), Stevens-Johnson syndrome (an acute mucocutaneous disorder usually 
precipitated by drugs or infection), and after chemical and thermal burns. (Dart. 2005; 
Power et al., 1995; Kruse and Cursiefen, 2008). 
 
IId. Reflex hyposecretion 
In an open eye, the lacrimal secretion is stimulated by the trigeminal sensory inputs 
arising from the naso-lacrimal channels and the surface of the cornea. Reduction of 
this stimulus decreases both tear secretion and the blink rate, which increases the 
evaporative loss of TF (Bourcier et al., 2005).  
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Bilateral sensory loss reduces both tear secretion and the blink rate. Topical anesthesia 
decreases the blink rate by about 30% and tear secretion by 60–75% (Nakamori et al., 
1997). 
Contact lens wear (especially hard lenses or extended wear) reduces corneal 
sensitivity, and increased tear osmolarity is measured among CL wearers (Nichols and 
Sinnott, 2006).  
Decreased corneal sensitivity is supposed to correspond to dry eye symptoms after 
corneal LASIK surgery, although neurotrophic deficiency or neuralgic disorder are 
other possibilities reasons for this (Nettune and Pflugfelder, 2010; Tuisku et al., 2007).  	  Diabetes mellitus has been noted as a risk factor for dry eye in several population 
studies (Moss et al., 2000; Moss et al., 2008). Diabetic sensory or autonomic 
neuropathy and the occurrence of microvascular changes in the lacrimal gland are 
supposed mechanisms of DES (Kaiserman et al., 2005).	  
 
Neurotrophic keratitis is characterized by extensive sensory denervation of the cornea. 
It is typically seen after herpes zoster ophthalmicus, or can be induced by trigeminal 
nerve section, injection, compression, or toxicity. Dry eye, diffuse punctuate keratitis, 
goblet cell loss, and peripheral or central ulcerative keratitis, which may even lead to 
perforation of the eye, are typical findings for neurotrophic keratitis (Bonini et al., 
2003). 
	  
III. Reflex Motor Block 
The nervus intermedius, a part of the facial nerve (cranial nerve VII), carries 
postganglionic parasympathetic nerve fibers to the lacrimal gland. Central damage to 
this nerve decreases lacrimal secretomotor function and leads to incomplete lid closure 
(lagophthalmos). 
  
Several systemic drugs can decrease lacrimal secretion. In population studies, 
antihistamines, beta blockers, antispasmodics, diuretics, tricyclic antidepressants, 
selective serotonin reuptake inhibitors (SSRIs), and other psychotropic drugs were 
independently and significantly associated with dry eye (Moss et al., 2000). 
 
2.2.3 Evaporative dry eye syndrome 
Evaporative dry entails that the surface of the eye is dry due to increased vapor of tear 
fluid in the presence of normal lacrimal secretory function. The excessive fade of tear 
fluid can occur due to intrinsic factors affecting the composition of TF or ocular 
structures, or due to extrinsic exposure to the ocular surface. The boundary between 
these two categories is not always clear. 
 
I. Intrinsic causes of dry eye 
 
Ia. Meibomian gland dysfunction 
MGD is the most common cause of evaporative dry eye (Foulks and Borchman, 
2010). Meibomian gland obstruction, seen in MGD, typically arises from acne 
rosacea, seborrheic dermatitis, or atopic dermatitis. 
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MGD can be simple, where the gland orifices remain in the normal position, or 
cicatricial, in which the secretion of lipids is hindered due to posteriorly drawn 
orifices. 
An insufficient or dysfunctional tear fluid lipid layer is associated with an increase in 
tear evaporation and the development of dry eye. 
 
Ib. Disorders of the lid aperture 
Increased ocular surface area and wider palpebral fissure, seen in endocrine 
exophthalmos, proptosis and in high myopia, correlates with increased TF evaporation 
(Rolando et al., 1985). The same effect is seen if poor lid apposition or lid deformity 
exposes the ocular surface to extensive evaporation. In addition, activities that induce 
upgaze are noted to induce the evaporation of TF (Tsubota and Nakamori, 1995).  
 
Ic. Low blink rate 
Reduced blink rate, which may occur physiologically during intensive gaze while 
reading or watching television, or due to a neurological disorder like Parkinson’s 
syndrome, exposes the surface of the eye to evaporation (Abelson et al., 2002). 
 
II. Extrinsic causes 
 
IIa. Ocular surface disorders 
Topically administrated drugs and preservatives can induce toxic damage to the ocular 
surface. Benzalkonium chloride (BAC), which causes surface epithelial cell damage 
and punctate epithelial keratitis, is the most common factor within this group (Uusitalo 
et al., 2010). Topical anesthesia can cause ocular surface damage through reducing the 
blink rate and deceasing sensory feedback to the lacrimal gland.	  	  	  	  	   
 
The normal development of goblet cells and expression of glycocalyx mucins are 
dependent of vitamin A (Tei et al., 2000). Thus, a deficiency of this vitamin can cause 
xerophthalmia, a potentially severe form of dry eye, which is still common in 
developing countries. Vitamin A deficiency can also cause damage to the structure of 
lacrimal acini, and thus patients with xerophthalmia may also have aqueous tear-
deficient dry eye. 	  
IIb. Contact lens wear 
Around half of CL wearers report dryness of the eyes, and this is by far the primary 
reason for CL intolerance. The increased evaporation, reduced feedback to stimulate 
lacrimal secretion, and raised temperature of TF are the main reasons for dry eye 
among CL wearers.   
 
IIc. Allergic conjunctivitis 
Ocular allergy has been noted to increase the prevalence of dry eye in population 
studies (Moss et al., 2008). Allergic Th2 type reactions to external antigens with a 
release of inflammatory cytokines leads to submucosal changes in the conjunctival 
and corneal epithelium. Surface damage and irregularities can lead to TF instability 
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and a local drying component. Lid swelling can cause lid apposition and hamper TF 
spreading, thus exacerbating the dry eye. 
 
2.2.4 Clinical examination of dry eye 
 
Symptom questionnaires 
Ocular irritation is a common complaint of patients presenting to an ophthalmologist. 
Anamnesis and symptom assessment are among most important “ophthalmic tools” 
for dry eye diagnosis. Often, only a few correct questions about ocular symptoms 
leads a clinician toward the diagnosis of dry eye. Several formal questionnaires have 
been developed to determine a score that would indicate dry eye diagnosis. These 
questionnaires, like the McMonnies (McMonnies and Ho, 1986) and Ocular Surface 
Disease Index (OSDI; Schiffman et al., 2000) are also used to determine the possible 
effect of dry eye treatments between repeated eye examinations. 
 
Staining of the ocular surface 
In dry eye, the corneal surface cells begin to disrupt; these small ruptures can be 
visualized with dyes. Lissamine green (triarylmethane) and more commonly used 
fluorescein dye diffuse in the fluid spaces between the cells; this staining can be seen 
when viewed with cobalt blue light. Rose Bengal (4,5,6,7-tetrachloro-2´,4´,5´,7´-
tetraiodofluorescein), a dye that was previously thought to stain dead cells, stains 
epithelial cells that are not covered by mucin and TF; thus, it can possibly visualize 
even milder dry eye changes (Doreen et al., 2004). 
To quantify and record the staining pattern of the cornea, different grading scales are 
used. In the literature, the van Bijsterveld system (1969), the Oxford system (Bron et 
al., 2003), and a standardized version of the NEI/Industry Workshop system (Lemp, 
1995) are typically mentioned, although no studies have been published that indicate 
that one grading system is innately better than another.  
 
Tear film break-up time 
Normal tear film continuously covers the surface of the eye. If an eye is kept open 
long enough, without blinking, the tear film will start to evaporate. The tear film 
break-up time (TFBUT) is used to measure the time in seconds that it takes for a tear 
film to evaporate, deteriorate, and finally break when the eye is open (Holly, 1993). 
To better visualize the tear film, fluorescein dye is applied to the lower eyelid fornix 
and the patient is asked to blink and then look straight ahead without blinking. The 
tear film is observed under cobalt-blue filtered light using a slit lamp microscope and 
the time that elapses between the last blink and the appearance of the first break in the 
tear film is recorded. According to a report of Lemp and Hamill (1973), a fluorescein 
TFBUT of 10 seconds or less is consistent with dry eyes diagnosis, although a 
correlation between a smaller fluorescein volume and shorter TFBUT times has been 
proposed (Abelson et al., 2002). Non-invasive break up time (NIBUT) refers to a 
technique/instrumentation (i.e., keratometer, hand-held keratoscope, or tearscope) 
where a reflection of an image on the surface of the eye without dye is monitored and 
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the appearance of distortion of the image is recorded (Mengher et al., 1985). NIBUT 
measurements are typically longer than TFBUT ones. 
 
Schirmer test 
The Schirmer test is used to determine the quantity of tear production. A filter paper 
strip, 35 mm x 5 mm size, is placed at the junction of the middle and lateral thirds of 
the lower eye lid for 5 minutes; the wetting of the paper is measured as the nearest 
integer of millimeters. Despite wide day-to-day and visit-to-visit variation, the 
Schirmer test is valuable in determining tear-deficient dry eye. The diagnostic cut-off 
for tear-deficient dry eye suggested by the van Bijsterveld study (1969) was ≤ 5.5 mm, 
though more recent recommendations have shifted the limit to < 5.0 mm of wetting 
(Pflugfelder et al., 1998; Vitali et al., 2002). Generally, wetting of more than 10 mm is 
considered to be a negative test result.  
The National Eye Institute workshop on dry eyes (2007) recommend performing the 
test with the eyes closed and refraining from the use of anesthetic eye drops before 
performing the test. In this way, the test is thought to measure both basal and reflex 
tear secretion; in contrast, when using anesthetic eye drops, the test is thought to 
measure only basic tear secretion. To measure the reflex tear secretion, the Schirmer II 
test may be performed by irritating the nasal mucosa with a cotton-tipped applicator 
before measuring tear production. For this test, wetting under 15 mm after five 
minutes is considered abnormal.  	  	  
Osmolarity 
The role of tear fluid osmolarity is well described in the pathogenesis of DES (Farris 
et al., 1986; Tomlinson et al., 2006). In both tear-deficient and evaporative dry eye the 
elevated tear osmolarity is regarded as a key feature that characterizes the condition of 
the ocular surface (DEWS, 2007). The recommended cut-off value for dry eye is >316 
mOsm/l (Tomlinson et al., 2006). Traditional methods to measure tear osmolarity 
were laborious, and high volumes of tears were needed. The equipment setup and 
maintenance, required specialist craft, length of the procedure, and potential errors due 
to evaporation of the test sample have hindered its acceptance and general application 
in clinical practice. 	  
Recently, special miniaturized devices, i.e., the Tearlab (OcuSense, Inc, San Diego, 
CA) and Advanced Instruments Model 3100 Tear Osmometer (Norwood, 
Massachusetts) have been introduced that measure osmolarity at a nanoliter scale 
(Tomlinson et al., 2010;Yildiz et al., 2009). These devices can easily be used in daily 
practice, as well as in dry eye research. Presumably, the measurement of tear 
osmolarity in general practice will notably increase in the near future.  
  
Cytology 
Differentiating between the symptoms and signs of ocular irritation originating from 
DES, allergy, or infection is sometimes challenging. In selected cases for sampling of 
the cells, taking mucin and/or ocular cytokines using impression or brush cytology can 
be helpful. In both, techniques a sample from the ocular surface is fixed and stained, 
and the profile of the cells is examined under the microscope. Additional staining with 
specific antigens may be used (Lopin et al., 2009). 
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None of these tests alone can offer a straight and absolute diagnosis of dry eye. 
Concerning an individual patient, a pattern of clinical tests and a classification scheme 
can provide a guide, but an expert clinician applying appropriate diagnostic criteria is 
needed to establish a diagnosis. 
 
 
2.2.5 Animal models of dry eye syndrome 
Some animal strains develop DES spontaneously. Quimby (1979) recognized 
similarities between dogs with severe DES and human Sjögren’s syndrome patients. 
This similarity has been confirmed by a study of dog lacrimal glands and conjunctiva, 
revealing a decreased apoptosis in the lymphocytes infiltrating the lacrimal gland and 
increased apoptosis in lacrimal acinar and conjunctival epithelial cells (Gao et al., 
1998). The incidence of spontaneous DES in the general canine population is 
unknown, although the prevalence is estimated to be highest for American cocker 
spaniels (20.6%), whereas mixed-breed and beagle dogs have lower prevalence rates 
of 11.5% and 1.2%, respectively (Kaswan et al., 1998). Spontaneous DES with the 
natural course of the disease in dogs provides a useful tool for dry eye studies. The 
large size of the dog’s globe compared with that of rodents provides benefits in ocular 
surface diagnostic tests and the collection of tears and mucin. The negative aspects of 
dog models include long and expensive maintenance, ethical questions, and 
difficulties in obtaining approval for experimental procedures on this species. In 
addition, the signs of DES tend to be considerably more severe in dogs than in 
humans. 
 
Beside studies one spontaneous canine DES, several experimental animal models have 
been generated to define the mechanisms of human DES; these are important tools for 
investigating the multiple factors that have been implicated in the pathogenesis of 
DES. The National Eye Institute Industry Workshop on Clinical Trials in Dry Eyes 
has produced a classification that separates DES models into two major types: tear-
deficient forms (including Sjögren’s syndrome and non-Sjögren’s tear-deficiency) and 
evaporative forms (Lemp, 1995). Several of the present DES models resemble tear 
deficiency or Sjögren syndrome-like autoimmune disease, since they diminish 
aqueous tear production via mechanical, autoimmune, or chemical effects on the 
lacrimal gland. 
 
The mechanical removal of the main lacrimal gland decreases basal tear production, 
measured by the Schirmer test, in dogs, cats, monkeys, and mice, but it does not cause 
significant changes in the ocular surface (Maitchouk et al., 2000; Barabino and Dana, 
2004). In rabbits, closure of the lacrimal gland excretory duct, together with removal 
of the nictitating membrane and Harderian glands, increases tear osmolarity; 
moreover, decreased conjunctival goblet cell density is seen (Gilbard et al., 1989). 
Thus, it seems that compensatory tear production by the accessory lacrimal glands 
alone may be sufficient to maintain a stable tear layer. 
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Human autoimmune Sjögren syndrome is characterized by a chronic inflammation of 
the lacrimal gland. The histological picture of affected glands shows infiltration of 
CD4+ T-cells that have a defect in Fas-mediated apoptosis (Van Blokland and Versnel, 
2002). In Sjögren syndrome, the aberrant presentation of autoantigens and class II 
major histocompatibility complex (MHC) molecules (cathepsins B and D, and 
ribonucleoprotein particle La/SSB proteins) by lacrimal gland acinar cells is capable 
of priming autoreactive T-cells (Yang et al., 1999). Several different animals are 
proposed to mimic the effect of abnormal CD4+ T-cell accumulation in the lacrimal 
glands. The non-obese diabetic (NOD) mouse model shows a lymphocyte infiltration 
of predominantly CD4+ Th1 cells in the lacrimal gland, as well as other organs, 
including the pancreas. TF secretion in these mice is reduced by 33% to 36% 
compared with wild-type (WT) animals (Humphreys-Beher et al., 1994). In IQI/Jic 
mice, the lymphocyte infiltration is restricted to salivary and lacrimal glands, making 
it more similar to the Sjögren-type model (Konno et al., 2003). In these mice, the 
development of complete dacryoadenitis takes around 9 months, which makes their 
use laborious. TGF-ß1 knockout (KO) mice show significant inflammatory cell 
infiltration in the lacrimal gland (McCartney-Francis et al., 1997). Unfortunately, 
these mice die between 3 and 4 weeks, just when they start to show increasing 
symptoms of a dry eye. The shortened life of the TGF-ß 1 KO mouse complicates 
their use as a dry eye model, particularly for studies involving the testing of medical 
approaches to dry eye. The autoimmune mediated models of DES also include the 
direct injection of cultured and activated T-cells into the rabbit lacrimal gland (Zhu et 
al., 2003) and activation of the rat immune system through the intradermal 
administration of a lacrimal gland extract in complete Freund’s adjuvant (Liu et al., 
1987). 	  
The lacrimal secretion of TF is controlled through a neural reflex from ocular surface 
to maintain adequate wetting of eye. Human neurogenic dry eye rises from a traumatic 
or disease-originated defect in this system. A milder neural feedback blockade is 
found among CL wearers, especially when hard contact lenses are used. Like in 
human neurogenic DES, animal models also show that a surgical removal of the 
parasympathetic nervation of the lacrimal gland leads to the development of DES 
(Salvatore et al., 1999; Toshida et al., 2007) A KO mice model of protein kinase C 
(PKC)-α, which plays a major role in the parasympathetic neural stimulation of 
lacrimal gland secretion, significantly decreases the production of TF (Hodges et al., 
2004). Clinical symptoms of DES are also found in neurturin-deficient mice, in which 
a defect of this neurotrophic factor for parasympathetic neurons and decreased 
parasympathetic innervation of lacrimal glands is presented (Song et al., 2003). 
To mimic neural defect, pharmacological models of anticholinergic (antimuscarinic) 
blockade have been engendered. The anticholinergic effect of topical 1% atropine 
sulfate has been shown to reduce lacrimal secretion significantly (Burgalassi et al., 
1999). Dursun et al. (2002) have presented a mouse model of DES in which 
transdermal scopolamine application is used to induce a pharmacologic blockade of 
cholinergic receptors in the lacrimal gland. In this model, significant DES changes 
were seen when neural blockade was combined with a continuous air flow that mimics 
environmental stressing conditions. 
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Animal models of evaporative DES are more infrequently studied than tear-deficient 
models. As tear lipid film imbalance and evaporative DES are common diseases of the 
eye, especially among elderly citizens, an experimental model that carefully mimics 
this condition is of utmost importance. The forced opening of the eyes with sutures or 
lid specula certainly leads to dry eye (Fujihara et al., 1995), but this procedure is far 
from ideal for studying the pathogenesis of DES, which is a chronic event. However, 
in the open eye, corneal epitheliopathy develops within a few hours; hence, this model 
can be used to evaluate the effect of artificial tears or other therapies. The mechanical 
cauterization of Meibomian gland orifices presented by Gilbard et al. (1989) and other 
lid surgery techniques definitely affect tear lipid film composition, but the normal 
appearance of palpebral aperture is easily hampered. Different mouse models of MGD 
(including aplasia, hypoplasia, and atrophy) have been created through mutant and 
transgenic techniques (Barabino and Dana, 2004).These models definitely have their 
advantages, even though a total absence of tear lipids is rare in human DES and the 
tear lipid film composition seems to differ from direct Meibomian secretion 
(Butovich, 2008). Animal models introduced for blepharitis show reduction in tear 
fluid lipid production associated with dry eye symptoms (Chan et al., 1995), but in these 
models the normal anatomical appearance of either lid or eye surface is also typically 
altered. However, the blepharitis itself induces ocular surface irritation and alters the 
immunological profile of the ocular surface, which is an important factor in the 
development of DES.  
 
The existing animal models of DES mimic pathological mechanisms underlying DES, 
but at the moment none of them seems to mimic precisely the complexity and 
chronicity of human dry eye. The bigger animals, like rabbits and dogs, have their 
advantages since they have bigger eyes; still, despite the small size of mice, the fairly 
well-known murine immunogenetics and the good availability of reagents and KO and 
transgenic strains make the mouse model very useful. Concerning the use of 
laboratory animals, it is important to remember that immortalized human corneal and 
conjunctival epithelial cell lines are also available (Gipson et al., 2003; Robertson et 
al., 2005).These models are useful in studying the effects of tear osmolarity, 
inflammatory mediators, and artificial tears on surface epithelia. To better understand 
the molecular mechanisms underlying in the pathogenesis of human DES, these 
models must be further studied and new models should be developed to describe 
evaporative DES in more detail. 
 
2.2.6 Treatment of dry eye  
Unfortunately, there is no curative treatment for DES because the pathogenesis of this 
disease remains unknown. Several treatment options are, however, available to aid in 
managing its symptoms. Current treatment recommendations are based on the severity 
of the disease (Lemp et al., 2007; Jackson, 2009). Lifestyle and nutrition modifications 
(Larmo et al., 2010), regular lid hygiene, and artificial tear supplements are typically 
sufficient against mild DES. Numerous artifical lubricant drops, gels and oinments are 
introduced to moisture the surface of the eye and to compensate reduced tear 
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production. These products also dilute tear osmolarity and wash out inflammation-
inducing agents from the ocular surface. Patients with moderate-to-severe symptoms 
are recomended to use additional anti-inflammatory medications. Pulse therapy with 
topical steroids can be applied while adverse side-effects limit their use. Topical 
cyclosporine seems to be well tolerated and effective in mild-to-moderate DES 
(Foulks, 2006). The muscarinic agonist pilocarpine administered orally has been used 
as a secretagogue to stimulate production of tear. It also temporarily increases the 
number of goblet cells (Aragona et al., 2006). In addition to medical therapy contact 
lenses, punctal plugs (Erwin et al., 2008) and moisture-retaining eyeglasses are used. 
In severe sight threatening situations autologous serum drops and surgery are 
recommended. Short term closure of lids, tarsorrhaphy, amnionic-membrane 
transplantation and limbal transplantations are used when satisfactory response can not 
be achieved with other medications or when severe DES has already damaged ocular 
stem cells.  
 
 
2.3 Classification of lipids  
International Lipid Classification and Nomenclature Committee defines lipids as a 
broad group of hydrophobic or amphipathic molecules that may originate entirely or in 
part by carbanion-based condensations of thioesters and/or by carbocation-based 
condensations of isoprene unit (Fahy et al., 2005). Lipids are generally considered to 
be molecules that are insoluble in water and soluble in organic solvents (Smith, 2000). 
Biological lipids refer to a broad group of molecules which includes fatty acids, 
waxes, eicosanoids, glycerolipids, phospholipids, sphingolipids, sterols, prenols, and 
fat-soluble vitamins A, D, E and K (Fahy et al., 2009). The main biological functions 
of lipids include major roles in energy storage, as structural components of the cell 
membranes, and as important signaling molecules. 
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Figure 4. A schematic representation of a lipid molecule. The hydrophilic headgroup 
is pointed towards the aqueous, whereas the hydrocarbon chains are embedded into 
hydrophobic membrane interior. Due to this in aqueous solutions lipid molecules are 
aggregated into 3-dimensional aggregates, such as micelles, bilayers, or tube-like 
hexagonal phases (adapted from www.schoolworkhelper.net).  
 
 
 
Fatty acids  
The fatty acids (FA) are the major lipid building blocks of complex lipids and 
therefore they are the most fundamental categories of biological lipids. FA molecule is 
constructed by chain elongation of a repeating series of methylene groups that leads to 
the hydrophobic character to this category of lipids. The simplest subclass molecule is 
a straight chain of saturated fatty acids containing a hydrophilic carboxylic acid 
terminus. The core hydrocarbon chain is typically between 4 to 24 carbons long, and it 
may be saturated or unsaturated with one or more double or even triple bonds between 
the carbon atoms. Double bonds cause the fatty acid chain to bend, which is important 
in the formation and function of cell membranes. Cyclic fatty acids containing three to 
six carbon atoms as well as heterocyclic rings containing oxygen, nitrogen and sulfur 
are found in specific subclasses. Examples of biologically important fatty acid 
derivatives are the eicosanoids, derived from arachidonic acid and eicosapentaenoic 
acid, which include prostaglandins, leukotrienes and thromboxanes.  
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Other major classes of FA derivatives are the fatty esters and fatty amides. Fatty esters 
include important biochemical intermediates such as wax esters, fatty acid thioester 
coenzyme A derivatives, fatty acid thioester ACP derivatives and fatty acid carnitines. 
Glycerolipids 
Glycerolipids (GL) are composed mainly of mono-, di- and tri-substituted glycerols. 
GLs serve as a main fat storage fat in animal tissues and the most well-known lipid of 
these fatty acid esters of glycerol is triglyceride (TG). In GL compounds the three 
hydroxyl groups of glycerol are usually esterified by different fatty acids. Additional 
subclasses of glycerolipids are glycosylglycerols, which are characterized by the 
presence of one or more sugar residues attached to glycerol (Påhlsson et al., 2001). Of 
these digalactosyldiacylglycerols are found in plant membranes and seminolipid from 
mammalian sperm (Hölzl and Dörmann, 2007).  
 
Glycerophospholipids  
Glycerophospholipids, also known as phospholipids (PL), are abundant in nature. PLs 
are main structures of the biological cell lipid bilayers. The most common PLs found 
in these membranes are phosphatidylcholine (PC or lecithin) 
phosphatidylethanolamine (PE) and phosphatidylserine (PS). PLs are also involved in 
metabolism and cell signaling, while PLs serve as binding sites for intra- and 
intercellular proteins and some PLs are either precursors or are themselves membrane-
derived second messengers. Glycerophospholipids are divided into different classes, 
based on the form of the polar headgroup at the sn-3 position of the glycerol backbone 
in eukaryotes and eubacteria, or the sn-1 position in the case of archebacteria. 
 
Sphingolipids 
Sphingolipids (SP) are a complex group of molecules that have a common sphingoid 
backbone synthesized from serine and a long-chain fatty acyl-coenzyme A, which is 
converted into ceramides, phosphosphingolipids, glycosphingolipids or other 
compounds. The major sphingoid base of mammals is commonly referred to as 
sphingosine. Ceramides (N-acyl-sphingoid bases) are a major subclass of sphingoid 
base derivatives. The major phosphosphingolipids of mammals are sphingomyelins. 
The glycosphingolipids are a versatile family of molecules composed of one or more 
sugar residues linked via a glycosidic bond to the sphingoid base. Sphingolipids 
protect the cell surface against harmful environmental factors by forming a 
mechanically stable and chemically resistant outer segment of lipid bilayer. Certain 
complex glycosphingolipids are involved in specific functions, such as cell 
recognition and signaling (Gratschev et al., 2009).  
 
Sterol lipids  
Sterol lipids (SL) are characterized by fused four-ring core structure. SLs are 
important components of membrane lipids such as the most well-known member, 
cholesterol, and its derivatives.  The steroids, which contain the same core structure, 
have different biological roles as hormones and signaling molecules: The C18 steroids 
include the estrogen family whereas the C19 steroids include the androgens. The C21 
subclass includes the progestogens, glucocorticoids and mineralocorticoids. The 
secosteroids, like different forms of vitamin D, are characterized by cleavage of the B 
 
 
  
 
33 
ring of the core structure.  Phytosterols commonly known as plant sterols can block 
cholesterol absorption in intestine and thus reduce cholesterol levels.  
 
Prenol lipids 
Prenol lipids are synthesized from the 5-carbon precursors isopentenyl diphosphate 
and dimethylallyl diphosphate. The simple isoprenoids (linear alcohols, diphosphates) 
are formed by the consecutive addition of similar core C5 structures called terpene 
units. Structures containing greater than 40 carbons are known as polyterpenes. 
Carotenoids are important simple isoprenoids that function as antioxidants and as 
precursors of vitamin A. Another biologically important class of prenol lipids is 
quinines, which contain an isoprenoid tail attached to a quinonoid core of non-
isoprenoid origin. Vitamin E and vitamin K are examples of these molecules. 
 
Saccharolipids 
Saccharolipids are molecules in which fatty acids are linked directly to a sugar 
backbone.  
This kind of structure matches to the membrane bilayers.  The most familiar 
saccharolipids are the acylated glucosamine precursors of the Lipid A component of 
the lipopolysaccharides in Gram-negative bacteria. Typical lipid A molecules are 
disaccharides of glucosamine, which are derivatized with seven fatty-acyl chains 
 
Polyketides 
Polyketides are synthesized as metabolites by polymerization of acetyl and propionyl 
subunits. Several polyketides are cyclic molecules whose backbones are often further 
modified by glycosylation, methylation, hydroxylation, oxidation or other processes. 
Many commonly used anti-microbial, anti-parasitic, and anti-cancer agents, like 
erythromycins, tetracyclines and antitumor epothilones are polyketides or polyketide 
derivatives. 
 
2.3.1 Lipoproteins and lipid transfer processes in human circulation 
Phospholipids, cholesterol, and triglycerides are the main lipids in human circulation. 
Many of these lipids have long hydrophobic hydrocarbon tails and are thus relatively 
insoluble in water. To transport lipids through the circulation, lipids are packed into 
water-soluble complexes referred to as lipoproteins. Most lipoproteins have a 
spherical structure that consists of a hydrophobic core of neutral lipids (mainly 
triacylglycerols and cholesteryl esters), surrounded by a polar surface monolayer of 
phospholipids, unesterified cholesterol, and apolipoproteins.  
The apolipoproteins solubilize the insoluble lipids and can act as cofactors for plasma 
enzymes and as ligands for cell surface receptors in tissue uptake. Six major classes of 
apolipoproteins (A, B, C, D, E, and H) and several subclasses are introduced.   
Lipoproteins constitute a heterogeneous population of particles that can be classified 
according to their densities. Traditionally, plasma lipoproteins have been separated 
from serum by sequential ultracentrifugation (Havel et al., 1955). Five major human 
plasma lipoproteins are chylomicrons (CM), very low-density lipoproteins (VLDL), 
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intermediate-density lipoprotein (IDL), low-density lipoproteins (LDL), and HDLs 
(Gotto et al., 1986). 
  
Lipoprotein metabolism can be divided into two major pathways: the transport of 
dietary lipids taken up from the intestine, referred to as the exogenous pathway; and 
the transport of lipids synthesized in the liver, the endogenous pathway. The transport 
of cholesterol from peripheral tissues to the liver, where it is converted into bile acids 
and excreted, is referred to as reverse cholesterol transport. 
 
 
HDL conversion
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HDL
HDL
preβ-HDL
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Figure 5. PLTP catalyses HDL conversion generating large fused HDL particles   
and preβ-HDL that participate in the reverse cholesterol transport from 
peripheral cells (Courtesy of Riikka Vikstedt). 
 
 
2.3.2 Lipid transfer proteins in lipoprotein metabolism 
The exchange of lipids between lipoprotein subclasses is performed by two closely 
related proteins: CETP and PLTP. PLTP and CETP belong to the lipid 
transfer/lipopolysaccharide binding protein family (LT/LBP), which also includes the 
lipopolysaccharide binding protein (LBP) and bactericidal/permeability increasing 
protein (BPI) (Day et al., 1994). LBP and BPI are able to bind and transfer bacterial 
endotoxins and lipopolysaccharide (LPS), thereby modulating the response to bacterial 
infection (Schumann et al., 1990). CETP is able to transfer neural lipids, triglycerides, 
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and cholesteryl esters between lipoprotein particles. PLTP transfer phospholipids, 
diacylglycerol (Rao et al., 1997), free cholesterol (Nishida and Nishida, 1997), R-
tocopherol (vitamin E) (Kostner et al., 1995), and lipopolysaccharide between 
lipoproteins and cells (Hailman et al., 1996; Levels et al., 2005). 
2.3.3 Characteristics of cholesterol ester transfer protein 
CETP, originally called lipid transfer protein I (LTP-I), was isolated from human 
plasma in the 1980s (Tall et al., 1983a; Albers et al., 1984).  
The human CETP protein contains 476 amino acids. The translated molecular mass of 
CETP is 53 kDa, but the mass estimated by sodium dodecylsulfate–polyacrylamide 
gel electrophoresis (SDS-PAGE) is 74 kDa (Drayna et al., 1987). The crystal structure 
of CETP was revealed in 2007 (Qiu et al., 2007). Based on this analysis, CETP is an 
elongated boomerang-shaped molecule. The protein contains four potential 
asparagine-linked glycosylation sites and a hydrophilic tunnel apparently mediating 
the lipid transfer. The human CETP gene is located in chromosome 16q12-16q21 
(Lusis et al., 1987). The CETP gene is expressed at high levels in adipose tissue, the 
heart, and the skeletal muscle, and at lower levels in many other tissues in several 
mammalian species. In humans, high levels of CETP expression are found in adipose 
tissue and the liver (Jiang et al., 1991), and CETP deficiency results in elevated 
plasma HDL levels (Inazu et al., 1990), which is associated with increased 
cardiovascular risk (Dullaart et al., 2007). 
2.3.4 Characteristics of PLTP 
This protein was firstly called lipid transfer protein II (LTP-II). It was found to 
directly facilitate the transfer of phospholipids from apoB-containing lipoproteins to 
HDL, but it was incapable of transferring cholesteryl esters or triglycerides (Albers et 
al., 1984; Tollefson et al., 1988). LTP-II was later called phospholipid transfer protein 
(PLTP; van Tol, 2002). 
 
Human PLTP contains 467 amino acids and is highly glycosylated (Day et al., 1994; 
Huuskonen et al., 1998). The computed molecular mass of mature human PLTP 
protein is 55 kDa, although the mass of human PLTP estimated by SDS-PAGE is 81 
kDa. The difference between the computed mass and the mass estimated by SDS-
PAGE may be due to N-glycosylation, since human PLTP contains six potential N-
glycosylation sites (Pussinen et al., 1997b). The human PLTP gene is located in 
chromosome 20q12-q13.1 (Day et al., 1994; Whitmore et al., 1995), and the mouse 
PLTP gene is localized in chromosome 2, which corresponds to human chromosome 
20 (LeBoeuf et al., 1996). 
  
In the molecular model of PLTP, it is constructed of a two-domain architecture with 
conserved N- and C-terminal lipid-binding pockets consisting of hydrophobic residues 
in each domain. In BPI, these pockets bind phospholipid molecules, whereas LBP can 
bind both LPS and phospholipids. Although only two specific lipid-binding pockets 
have been identified in PLTP, it can accommodate up to 43 mol of 
phosphatidylcholine and 13 mol of cholesterol/mol of PLTP. The lipid-binding 
pockets of the PLTP molecule might be needed for specific lipid transfer of this 
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protein, while the rest of the associated phospholipids may be needed for proper 
folding of the protein and stabilizing the enzymatic activity. 
 
In humans, PLTP expression is highest in the placenta, pancreas, and adipose tissue, 
and it is found at moderate levels found in the liver, kidney, and heart (Day et al., 
1994; Huuskonen et al., 1998). PLTP mRNA is also expressed in alveolar type II 
epithelial cells of the lungs, and its expression is induced during hypoxia and in 
emphysema (Jiang et al., 1998).  
 
In vitro studies have identified a number of functions for PLTP in lipoprotein 
metabolism (Albers and Cheung, 2004). PLTP displays two major functions in 
circulation: i) it transforms HDL particles in a conversion process whereby large fused 
HDL particles and preβ-HDL are generated. These two new particle populations can 
participate in cholesterol removal from macrophage-foam cells in a process called 
reverse cholesterol transport (Vikstedt et al., 2007, Figure 5); ii) it transfers post-
lipolytic VLDL surface phospholipids to HDL (Figure 6).  
 
 
       
 
                       
                     Figure 6.  PLTP-facilitated postlipolytic transfer of VLDL surface 
 phospholipids to HDL (Courtesy of Riikka Vikstedt). 
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A role for PLTP in atherogenesis has been suggested (Cheung et al., 2006). Functions 
of PLTP which may influence the formation of atherosclerotic lesions include the 
generation of acceptors for lipid efflux from cells, regulation of plasma HDL levels, 
protection of lipoproteins from oxidation, and regulation of production of atherogenic 
lipoproteins (Jiang et al., 2001). In human plasma, two distinct forms of PLTP are 
present, one with high activity (HA-PLTP) and the other with low activity (LA-PLTP) 
(Oka et al., 2000). These two forms are associated with different apolipoproteins 
during their purification (Kärkkäinen et al., 2002). Interestingly, PLTP was secreted 
only in an active form from HepG2 cells associated with apoE (Siggins et al., 2003). 
Although the role of PLTP in lipoprotein metabolism and atherogenesis has been 
intensively studied in gene-targeted mouse models and using in vitro experiments, the 
physiological role of PLTP in human metabolism is far from resolved. Another 
unsolved question is: By what mechanisms do PLTP and CETP mediate lipid transfer 
between the lipid donors and acceptors? On the basis of kinetic evidence, it has been 
suggested that CETP facilitates lipid transport by a shuttle mechanism rather than by 
forming a ternary complex between CETP, HDL, and acceptor lipoprotein particles 
like VLDL and LDL (Connolly et al., 1996). In favor of this model of lipid transport, 
it was later demonstrated that CETP can absorb lipids from phospholipid monolayers 
residing at the air-water interface (Weinberg et al., 1994).  
 
 
2.3.5 Animal models of phospholipid transfer protein 
The physiological role of PLTP in lipoprotein metabolism has been extensively 
studied using different mouse models. Both PLTP-deficient and overexpression 
models, as well as the macrophage-specific targeting of PLTP in mice, have been 
applied.  
  
PLTP deficient mice 
In order to evaluate the role of PLTP in lipoprotein metabolism Jiang et al. created a 
PLTP knockout mouse model (Jiang et al., 1999). In chow-fed mice, targeted mutation 
of the PLTP gene resulted in strong decreases in HDL, but no changes in non-HDL 
lipid or apoAI levels. Low HDL levels in PLTP KO mice arise from a marked increase 
in HDL catabolism (Qin et al., 2000). The increased HDL catabolism is possibly 
related to a decrease in the phospholipids of the HDL particles. On a high-fat diet, 
both HDL and non-HDL lipoprotein levels were altered (Jiang et al., 1999), 
suggesting accumulation of surface components of triglyceride rich lipoproteins. 
These findings show the importance of PLTP activity for the transfer of surface 
components of trilyceride-rich lipoproteins to HDL. The decreased plasma levels and 
production rate of apoB-containing lipoproteins could explain why PLTP KO mice 
have decreased susceptibility to develop atherosclerosis (Jiang et al., 2001). An other 
explanation for the protective effect seems to be that circulating apoB lipoproteins are 
protected from oxidation due to the increased availability of free plasma vitamin E 
(Jiang et al., 2002). PLTP-deficient mice also exhibit an anti-inflammatory effect due 
to significantly lower levels of IL-6 (Schlitt et al., 2005). 
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PLTP overexpressing mice 
Overexpression of PLTP drives to the formation of larger HDL species, demonstrating 
the involvement of PLTP in HDL remodeling in vivo (Ehnholm et al., 1998). The 
overexpression of PLTP also lowers the total HDL levels of targeted mice, while it 
induces increased generation of preβ−HDL (Föger et al., 1997). Although preβ−HDL 
is only a minor subfraction of total HDL, it is very efficient acceptor of cellular 
cholesterol in the reverse cholesterol transport and thus it was suggested that 
overexpression of PLTP might have atheroprotective potential. However, the elevation 
of PTLP activity levels increased the susceptibility to development of atherosclerosis 
in dose-responsive manner (van Haperen et al., 2002) and also atherosclerotic lesions 
in proximal aorta were increased (Yang et al., 2003). The plausible explanation for 
this seems to be the decreased plasma vitamin E levels, which leads to increased 
oxidation of lipoproteins.  
 
Macrophage-specific targeting of PTLP in mice 
Macrophages, that are a key component of atherosclerotic lesions through foam cell 
formation, have been demonstrated to highly express PLTP (Desrumaux et al., 2003). 
In order to elucidate the role of macrophage-derived PLTP in atherosclerosis several 
bone marrow transplantation studies has been performed. The results have been 
controversial as both atheroprotective and pro-atherogenic results have been published 
(Valenta et al., 2008; Vikstedt et al., 2007), indicating that the small differences 
between the experimental conditions employed grossly affect the results. Thus,  the 
role of macrophage-PLTP in lipoprotein metabolism and in the development of 
atherosclerosis is far form resolved. 
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3 AIMS OF THE STUDY 
 
 
The aim of the present study was to investigate the role of PLTP lipid transfer 
mechanisms in TF and evaluate the effect of PLTP in dry eye. The specific aims were: 
 
 
1. To investigate the presence and activity of the lipid transfer proteins PLTP 
and CETP in tears. (I) 
 
2. To characterize the molecular mechanisms of PLTP-mediated lipid transport 
in air-water surfaces and in TF. (II, III) 
 
3. To clarify PLTP-protein interactions in TF. (III) 
 
4. To evaluate the effects of PLTP knock-out on the mouse ocular surface and 
compare these results to experimentally induced dry eye (EIDE). (IV) 
 
5. To determine the PLTP activity among human dry eye patients and compare 
it to other dry eye tests. (IV)  
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4 MATERIALS AND METHODS 
4.1. Materials  
Antibodies:  
Mono- (Mab59 IgG) and  
polyclonal (R290 IgG) antibodies against PLTP 
 
Produced and purified as described 
by Huuskonen et al. (2000). 
A monoclonal antibody against human CETP, TP-2 
 
A kind gift from Dr. Yves Marcel, Ottawa, Canada. 
Polyclonal antibodies against  
human apoA-I and apoE 
 
Raised in New Zealand white rabbits 
using antigens purified from human plasma. 
Monoclonal mouse anti-human mucin 5AC 
(MUC 5AC, clone 2-12M1)  
 
Purchased form AbD Serotec (Oxford, UK). 
Enzyme conjugated secondary antibodies 
goat anti-mouse IgG Horseradish peroxidase (HRP) 
and goat anti-rabbit IgG HRP 
 
Purchased from Bio-Rad  
(Bio-Rad Laboratories, CA, USA). 
 
Monoclonal antibodies against lipocalin and serum 
amyloid A  
 
Purchased from Abcam (Cambridge, UK). 
Proline rich-protein 1 monoclonal antibodies  
 
Purchased from Sigma (St. Louis, MO, USA). 
Polyclonal rabbit anti-occludin  
 
Purchased from Zymed (San Francisco, CA). 
Alexa 488-conjugated goat anti-rabbit 
immunoglobulin 
Purchased from Molecular Probes (Eugene, OR). 
 
Proteins and lipids:  
PLTP Purified from human plasma 
as described by Kärkkäinen et al. (2003). 
 
Purified tear lipocalin A kind gift from Dr. B. Redl  
(University of Innsbruck, Austria). 
 
HDL3 isolated from human plasma  
by sequential ultracentrifugation. 
 
Reconstituted apolipoprotein A-I (apoA-I) Prepared by the cholate dialysis method. 
 
Bovine submaxillary gland mucin (type I-S) and 
lactoperoxidase 
 
Purchased from Sigma (St. Louis, MO, USA). 
 
Lysozyme Purchased from Abcam (Cambridge, UK). 
 
POPC (palmitoyloleoylphosphatidylcholine) Purchased from Avanti (Birmingham, AL). 
 
[14C]DPPC (dipalmitoylphosphatidylcholine) Purchased  from Amersham Biosciences. 
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4.2 Methods 
The methods used in this thesis are listed in the table below. Details can be found in 
the original publications and references. 
 
 
 
Method                                   Original publication    References 
 
 
Asymmetrical field-flow fractionation  II 
CETP activity assay  I Groener et al., 1986 
Collection of human TF samples  I, IV  
Corneal and eyelid histopathology IV  
Corneal permeability to carboxyfluorescein IV 
Dot-blot analysis  III 
Electrochemiluminescence detection I, IV Towbin et al., 1979 
Heparin-Sepharose chromatography I, III 
Immunoblotting of 
PLTP, CETP, apoA-I, and apoE I Towbin et al., 1979 
 
Immunohistochemistry  III 
Immunoinhibition of PLTP activity I  
Immunoprecipitation of PLTP complex III 
Induction of EIDE  IV Dursun et al., 2002 
Lipid monolayer preparation  II 
MALDI-TOF mass spectrometry III   
Measurement of tear osmolarity IV 
Occludin immunohistochemistry IV  
Phospholipidation of BSM and ovomucin III Matz et al., 1982 
PLTP activity assay  I Damen et al., 1982 
PLTP ELISA   I Towbin et al., 1979 
Preparation of apolipoprotein vehicles II Jauhiainen et al., 1993 
Purification of ovomucin  III Hiidenhovi et al., 1999 
Purification of PLTP  II Jauhiainen et al., 1993 
Radiolabeling of PLTP and SUVs II Jauhiainen et al., 1999 
SDS-PAGE   III  
Sequence homology search  III     www.matrixscience.com/search_form_select.html 
Size-exclusion chromatography (SEC) I, III 
Western blotting  I, III, IV 
Quantification of apoA-I and apoE I Kärkkäinen et al., 2002 
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4.2.1 Tear fluid analysis 
Collection of tear fluid 
Individual TF samples (approximately 20 µL) were collected from the lower 
conjunctival sac using Blaubrand intramark 10 µL micropipets (Brand GMBH, 
Wertheim, Germany). The samples were immediately cooled to +4 °C and stored at -
70 °C until analyzed. To obtain large amounts of TF tear production was stimulated by 
onion vapor. Pooled samples were collected from 11 subjects, and stored like 
individual samples. Clinical investigation of the subjects before collection of tear fluid?
showed no signs of ocular inflammation or allergy. 
 
Measurement of tear PLTP and CETP concentration and activity 
The concentration of PLTP in TF and plasma was determined using an enzyme-linked 
immunosorbent assay (ELISA). PLTP activity was recorded by measuring the transfer 
of [14C]-PC from radiolabeled PC vesicles to unlabeled HDL3 acceptors. 
CETP activity was determined from the rate of transfer of radiolabeled cholesterol 
ester from LDL to HDL. 
 
Immunoinhibition of tear PLTP activity  
Increasing amounts of rabbit polyclonal anti-PLTP IgG (80-1280 µg) were added to 
human tear fluid (5 µL) and incubated for 2 h at room temperature. After volume 
adjustments, 20 µL aliquots were used to analyze PLTP activity. Control incubations 
contained PBS instead of anti-PLTP IgG. 
 
Size-Exclusion Chromatography of Tear Fluid Proteins 
Catalytically active PLTP can be separated from the catalytically low activity form by 
size-exclusion chromatography or by using the heparin-binding properties of the 
active protein. Pooled TF samples (500 µL) was subjected to a fast-performance liquid 
chromatography on a Superose 6 HR (10x30 cm) size-exclusion column (Amersham 
Pharmacia Biotech). The column was equilibrated with PBS (150 mM NaCl and 10 
mM Na-phosphate at pH 7.4) containing 0.05% Tween 20. Chromatography was 
performed at a flow rate of 0.5 mL/min, and 0.5 mL fractions were collected for PLTP 
activity and mass measurements. 
 
Heparin-Sepharose Chromatography of Tear Fluid Proteins 
Pooled TF samples (70 µL) was mixed with 930 µL of buffer A (25 mM Tris-HCl at 
pH 7.4 containing 1 mM EDTA) and applied on 1 mL Hi-Trap Heparin-Sepharose 
column (Amersham Pharmacia Biotech) pre-equilibrated with buffer A. After elution 
of nonbound material, buffer B (buffer A supplemented with 0.5 M NaCl) was applied 
and 0.5 mL fractions were collected at a flow rate of 0.5 mL/min. After buffer B, the 
elution was continued with buffer C (buffer A supplemented with 1 M NaCl). 
Collected fractions were analyzed for PLTP concentration and activity. 
 
Measurement of tear fluid osmolarity 
Human TF osmolarity was measured with Tearlab osmometer (Ocusense Inc., San 
Diego, CA).  
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Measurement of mouse tear production 
Mouse tear production was measured before and 7 days after induction of EIDE. A 
half of Schirmer paper was applied in the lateral canthus for 60 seconds. Wetting of 
the paper was measured in millimeters. 
 
4.2.2 Lipid monolayers 
Lipid monolayer, residing on an air-buffer interface, provides access to measure the 
penetration of protein(s) into membrane by monitoring the increase in surface 
pressure. Protein derived desorption of radioactively labelled lipids from monolayer 
can be measured from aqueous subphase.  
 
Interaction of PLTP with Lipid Monolayers 
Penetration of PLTP into lipid film, POPC/DPPC or [14C]-DPPC  (80:20 ratio)  was 
measured using circular Teflon-coated wells (1200 µL). Surface pressure (π) was 
monitored with a Wilhelmy wire attached to a microbalance (µTroughS; Kibron Inc., 
Helsinki, Finland) and connected to a Pentium personal computer. The monolayer 
with different initial surface pressures (π0) was spread on an air-buffer (25 mM 
sodium phosphate buffer and 150mM NaCl, pH 6.8) interface by dropwise addition of 
phospholipid-chloroform solution from a Hamilton syringe. The resulting monolayers 
were allowed to equilibrate for 15 min before addition of PLTP to the subphase. The 
increment in π after the addition of PLTP was complete in <60 min, and the difference 
between π0 and the value observed after binding of PLTP into the film (πf) was taken 
as Δπ.?
?
Absorption of DPPC from the monolayer?
A monolayer of [14C]-DPPC was spread on an air-buffer interface to an initial surface 
pressure of ~7 mN/m. The surface pressure was controlled as described above. 
Monolayer was allowed to equilibrate before the addition of 10 µL of either HA-
PLTP, LA-PLTP, HDL3 or a mixture into the subphase. Lipid/buffer system was 
incubated for 3 h, and one-fourth (300 µL) of the subphase volume was collected for 
liquid scintillation counting (Wallac Winspectral 1414 liquid scintillation counter, 
Turku, Finland). 
 
4.2.3 Asymmetrical Flow Field-Flow Fractionation 
Miniaturized and conventional asymmetrical flow field-­‐flow fractionation (mAsFlFFF 
and AsFlFFF, respectively) were utilized. Detection was performed with a UV/vis 
detector (HP1050 model 79853C, Tokyo, Japan).  For both systems, a regenerated 
cellulose acetate ultrafiltration membrane with a molar mass cutoff of 10 kDa 
(DSSRC70PP, Nakskov, Denmark) was laid on top of the porous frit. An HPLC pump 
(model PU-980, Jasco International Co., Ltd., Tokyo, Japan) was used to deliver 
carrier solution during the injection-­‐relaxation-­‐focusing and running periods. The 
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outlet flow from the channel was monitored at 254 or 280 nm. The carrier liquid used 
in AsFlFFF was 10 mM phosphate buffer, 150 mM NaCl, 1 mM EDTA, and 0.02% 
NaN3 at pH 7.4. 
 
 
AsFlFFF and Lipid Transfer Assays 
A mixture of the donor (DPPC small unilamellar vesicles, 15 µL) and of acceptor 
(HDL3, 250 µg) were placed in polypropylene microsample tubes (Eppendorf), and 
diluted to 400 µL with the phosphate buffer solution (10 mM phosphate, 150 mM 
NaCl, and 1 mM EDTA, pH 7.4). After incubation (45 min) the sample was diluted to 
10 mL with the same buffer and then injected to AsFlFFF at 1.0 mL/min for 10 min. 
To elucidate the ability of PLTP to transfer lipids from donor SUVs to acceptor 
particles, either LA (c =32 µg/mL) or HA (c=10-15 µg/mL) PLTP was added 
separately to the mixture before incubation. To demonstrate the actual transfer of the 
lipid and movement of the PLTP protein itself, [14C]DPPC-labeled SUV and [35S]-
labeled PLTP were used. After AsFlFFF the radioactivity of collected fractions was 
measured with liquid scintillation counting. 
 
4.2.4 Detection of PLTP-protein interactions 
To determine possible PLTP-protein interactions in tear fluid Heparin-Sepharose 
affinity chromatography, immunoprecipitation, dot-blot analysis and Size Exclusion 
Chromatography of mucin-PC and PLTP were used. 
 
Heparin trapping of PLTP 
Pooled tear fluid samples (400 µl) were applied to a 1 mL HiTrap Heparin column 
(GE Healthcare, Buckinghamshire, UK) that was equilibrated with buffer A (25 mM 
Tris-HCl buffer, pH 7.4 containing 1 mM EDTA). The column was washed with 
Buffer A (flow rate 0.5 mL/min) and the bound material was eluted with a 0.5 M NaCl 
in buffer A. The active PLTP fractions were combined and dialyzed against buffer A 
and then applied to same 1 mL HiTrap Heparin column. The bound PLTP was eluted 
with a linear 0-0.5 M NaCl gradient. The fractions were analyzed for PLTP activity. 
The active fractions were pooled and concentrated with nanostep 10K omega system 
(Palli, Life Sciences, U.K.). Lyophilized material was loaded to 12.5% SDS-PAGE 
gel and stained with Coomassie R-250 stain. The detected protein bands were cut apart 
and transferred to mass spectrometry. 
 
Immunoprecipitation of PLTP-protein complex  
Tear fluid samples and pure proteins identified by mass spectrometry were studied. 
Anti-PLTP MAb 59 or rabbit polyclonal anti-PLTP (R290) was added to Protein G 
(100 µl) and incubated for 60 min, after which the beads were washed two times with 
TBS-Tween. Either pooled tear fluid samples (100 µl) or purified active PLTP and 
candidate proteins were added to the beads and incubated overnight. Protein G-anti-
PLTP IgG bound material and supernatants were analyzed with SDS-PAGE using 
buffer with or without 2 mM β-mercaptoethanol. Adhered proteins were detected with 
Western blot analyses. Immunoprecipitation of the tear fluid PLTP-mucin complex 
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was performed also using polyclonal anti-MUC5B antibody.  Separation on non-
reducing 5% SDS-PAGE was done for mucin. PLTP was analyzed using 12.5 % SDS-
PAGE under reducing conditions. The mucins were detected with the monoclonal 
antibody and PLTP with MAb 59.  
 
Dot-blot analysis 
The dot-blot assay was used to determine the PLTP-mucin interactions. Increasing 
concentrations (0 – 45 µg/well) of either ovomucin or BSM were transferred onto 
nitrocellulose membranes using a Minifold (Amersham Pharmacia Biotech) Slot Blot 
Apparatus. The membranes were blocked with defatted milk (5% wt/vol in TBS, 0.1% 
Tween 20, pH 7.5) and washed twice with TBS-Tween 20. Membranes were 
incubated with HA-PLTP (25 µg) and controls without PLTP over night and 
membranes were washed with TBS-Tween 20. Bound PLTP protein was detected by 
using monoclonal anti-PLTP MAb 59 antibody. Bovine mucin and ovomucin were 
detected with the monoclonal anti-MUC5AC antibody. 
 
Size Exclusion Chromatography of mucin-PC and PLTP 
Radioactively labeled ([14C]-DPPC) mucin-PC were incubated together with purified 
active PLTP for 30 minutes. Samples were subjected to fast-performance liquid 
chromatography on a Superose 6HR size-exclusion column (Amersham Pharmacia 
Biotech). Chromatography was performed at a flow rate of 0.5 mL/min, and 0.5 mL 
fractions were collected for radioactivity, phospholipid and protein measurements. 
Radioactivity of the collected fractions was measured with liquid scintillation counting 
(Wallac LS Counter, Turku, Finland). Phospholipid concentration was assayed using a 
commercial kit (DiaSys, Holzheim, Germany). Dot-blot analysis of the proteins was 
performed as described above using anti-PLTP and anti-mucin antibodies.  
 
4.2.5 Examination of ocular tissues 
 
Lacrimal gland samples 
Pieces of main lacrimal gland and the adjacent conjunctiva were obtained from nine 
subjects with whom the lacrimal gland was excised for diagnostic purposes.  
Sections of formalin-fixed paraffin-embedded tissues were incubated with monoclonal 
antibodies to PLTP, MAb 59 and MAb66.  Immunohistochemical stainings were 
performed using a commercial Elite ABC Kit (Vectastain, Vector Laboratories, 
Burlingame, CA). Non-immunized mouse serum served as a primary antibody. The 
bound peroxidase activity was visualized with a specific substrate, 3-amino-9-
ethylcarbazole (Sigma, St. Louis, MO) solution (0.2 mg/mL in 0.05 M acetate buffer 
containing 0.03% perhydrol; pH 5). The slides were stained with hematoxylin, washed 
and mounted in Aquamount (BDH, Poole, UK). 
 
Corneal and eyelid histopathology  
Eyes and eyelids from mice were fixed in 10% formalin and embedded in paraffin. 
Sections (5 µm) were prepared and stained with hematoxylin-eosin (HE) and Periodic 
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acid-Schiff (PAS). Sections from three different eyes in each group were examined 
and photographed with a Nikon Eclipse TE2000-E (Nikon Corp., Tokyo, Japan) 
microscope equipped with a Nikon Digital Sight DS-5MC camera. The corneal 
epithelial damage was assessed by counting the number of detaching apical cells from 
a full microscope field-of-vision from three separate tissue sections, using a x20 
objective. Three mice were evaluated in each treatment group. 
Corneal permeability to carboxyfluorescein 
CF (1 µL of a 0.3 % solution) was applied to the mouse ocular surface. After 10 
minutes the mice were sacrificed with high-dose carbon dioxide. Corneas without 
scleral rims were excised, rinsed twice with 200 µl BSS, weighted and placed in 100 
µl BSS. The CF concentration of the solution was measured (excitation 490 nm, 
emission 535 nm) using Wallac Victor2 1420 Multilabel Counter (Beckman Coulter, 
Fullerton, CA). 
Occludin Immunohistochemistry 
Whole mice eyes were fixed in formalin, embedded in paraffin and mounted on 
chromium-gelatin-treated slides in 5 µm sections. The sections were soaked in xylene, 
rehydrated in graded alcohol series (100-70 %) and treated (12 min at 37 oC) with 
pepsin (0.5 % w/vol) containing 0.1 M HCl. The sections were permeabilized and 
blocked with 0.1 M Na2HPO4 (PB) containing 0.2 % Triton X-100 and 10 % normal 
goat serum for 60 min and labeled overnight with polyclonal rabbit anti-occludin 
primary antibody (dilution 1:25) diluted in 0.1 M PB containing 0.1% Triton X-100 
and 2.5% normal goat serum. Tissues without primary antibody served as negative 
controls. Sections were labeled for 1 hour with Alexa 488-conjugated goat anti-rabbit 
immunoglobulin. The stained sections were rinsed in PB and mounted with 
Aquamount (BDH Chemicals, Poole, UK). The sections were examined under 
fluorescent illumination (excitation 460-500 nm, emission 510-560 nm) by Nikon 
Eclipse TE2000-E (Nikon Corp., Tokyo, Japan) microscope equipped with a Nikon 
Digital Sight DS-5MC camera. 
4.2.6 Experimentally induced dry eye 
Induction of EIDE was achieved by cholinergic receptor blockade. Transdermal 
scopolamine patches were applied by cutting the patches into four pieces, wrapping 
them around the depilated midtail, and securing them with cellophane tape. Patches 
were reapplied on days 0, 2, 4, and 6. 
 
4.3 Animals 
C57Bl/6 WT (Charles River, USA) and C57Bl/6 PLTP-KO mice (Jiang et al., 1999) 
were bred at Taconic Europe Facilities, Denmark (http://www.taconic.com), and then 
transferred to the National Public Health Institute, Helsinki, Animal Care Centre for 
further breeding. The mice were housed in a room under controlled temperature 
(23 ± 1 °C) and light cycle, with free access to water and standard mouse chow (18% 
protein, 5% fat; Harlan Teklad Global Diets, Denmark, No. 2018). 
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4.4 Ethical and patient information 
This study was performed according to the principles of the Declaration of Helsinki, 
and approved by the Ethics Review Committee of the Department of Ophthalmology 
(University of Helsinki). Informed consent was obtained from each human subject. 
The permission to use tissue samples was obtained from the Finnish National 
Authority for Medicolegal Affairs (TEO). 
All of the animal experiments were conducted under the National Public Health 
Institute guidelines (license # KTL 2004-02) for the humane treatment of laboratory 
animals. All procedures in the study protocol adhered to the ARVO Statement for the 
Use of Animals in Ophthalmic and Vision Research.  
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5 RESULTS 
 
5.1 PLTP is an active part of human tear fluid 
To gain insight into the mechanism of tear film formation, the occurrence of the two 
lipid transfer proteins, PLTP and CETP, in human TF was investigated.  
Western blotting of human TF and plasma using a monoclonal anti-PLTP antibody 
revealed that both tear fluid and plasma displayed a single 80 kDa band corresponding 
to the predicted molecular weight of the mature, highly glycosylated form of human 
PLTP (Figure 7). 
 
 
                 
Figure 7. Western blot analysis of phospholipid transfer protein in tear fluid. 
Plasma samples derived from seven normolipidemic subjects were run on a SDS-
PAGE and after protein transfer to nitrocellulose PLTP was detected with a 
monospecific antibody against human PLTP.  
 
 
5.1.1 Concentration and transfer activity of human tear fluid PLTP 
The mean PLTP concentration in TF was 10.9 ±? 2.4 µg/mL. In plasma, the PLTP 
concentration was 4.5 ±	   0.9 µg/mL (p <	   0.001) (I, Fig. 2A). Thus, the PLTP 
concentration seems to be higher in TF than in plasma. 
The mean phospholipid transfer activity in TF was 15.1 ±	   1.8 µmol/mL/h and in 
plasma was 8.9 ± 1.8 µmol/mL/h (p <	  0.001) (I, Fig. 2B).  
The specific activity of PLTP in tear fluid compared to plasma was found to be 
significantly lower, 1.4 ±	  0.3 nmol/µg/h versus 2.1 ±	  0.6 nmol/µg/h (p <	  0.006) (I, 
Fig. 2C). No correlation between tear and plasma PLTP concentration and activity 
was observed. 
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The contribution of PLTP in tear phospholipid transfer was studied by heat 
inactivation (Groener et al., 1986) (58 °C for 60 min) and by immunoinhibition with a 
polyclonal antibody specific for PLTP (Huuskonen et al., 2000). Heat inactivation of 
PLTP resulted in the loss of transfer activity. In addition, immunoinhibition with a 
polyclonal antibody specific for PLTP resulted in the almost total inhibition of PLTP 
activity (I, Fig. 3). Tear lipocalin did not show phospholipid transfer activity in the 
assay developed to measure PLTP-facilitated phospholipid transfer (I). 
 
 
5.1.2 Only the high-activity form of PLTP is present in human tears 
Catalytically active plasma PLTP can be separated from the catalytic low-activity 
form by size-exclusion chromatography (SEC) or by using the heparin-binding 
properties of the active protein form (Oka et al., 2000; Kärkkäinen et al., 2002). 
 
When analyzed by SEC, PLTP activity and PLTP protein coeluted in fractions, 
corresponding to an apparent molecular weight of 160–170 kDa (I, Fig. 4B and 
inset). Catalytically inactive PLTP was not observed in any of the fractions. 
During heparin-­‐Sepharose-affinity chromatography, both PLTP activity and mass 
bound to the column and could be eluted with 0.5 M NaCl (I, Fig. 5). The recovery of 
PLTP activity was over 90% and that of the PLTP protein mass was about 80%. These 
results demonstrate that PLTP in TF has similar characteristics to the high-activity 
form of PLTP present in human plasma. 
 
5.1.3 Human tear fluid contains neither apolipoprotein A-I, E nor 
CETP 
In human plasma, LA-PLTP is found to be associated with apolipoprotein (apo) A-I, 
while HA-PLTP associates preferentially with apoE (Kärkkäinen et al., 2002, Siggins 
et al., 2003). This suggests that PLTP activity may be regulated by the apoE/apoA-I 
molar ratio in the PLTP-apolipoprotein complex. Because PLTP is highly 
hydrophobic, it was reasoned that it might also be associated with these 
apolipoproteins in TF. TF was analyzed for the presence of these apolipoproteins 
using Western blotting and ELISA. However, neither apoA-I nor apoE could be 
detected (I). 
 
CETP neither could be detected in TF by Western blotting using a monoclonal 
antibody. The presence of other possible neutral lipid transferring activities in TF was 
studied by an isotopic assay, which measures the transfer of radioactive cholesteryl 
ester from LDL to HDL3. Consistent with the lack of immunoreactive CETP, no 
cholesteryl ester transfer activity could be detected in TF. PLTP and CETP can be 
separated by heparin-Sepharose-affinity chromatography (Tollefson et al., 1988), 
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whereby PLTP is quantitatively bound to heparin while CETP is not. In the flow-
through fractions of heparin-Sepharose chromatography, we could not detect either 
CETP activity or immunodetectable CETP. These observations strongly suggest that 
TF does not contain CETP (I). 
 
5.2 Mechanism of phospholipid transfer protein –mediated lipid 
transfer 
To elucidate the mechanism(s) by which PLTP transfers its principal substrate, 
phospholipids, series of monolayer and flow field-flow fractionation experiments were 
conducted. The principle of these methods is presented in figures 8 and 9. 
 
5.2.1 Interaction of phospholipid transfer protein with phospholipid 
monolayers 
Phospholipid monolayers containing POPC/DPPC (80:20 molar ratio) were prepared 
in Teflon-coated wells to assess the partitioning of PLTP between the phospholipid 
monolayer and the aqueous subphase as a function of monolayer surface pressure. The 
initial surface pressures ranged from 4 to 41 mN/m.  
 
Either HA-PLTP (1.6 µg) or LA-PLTP (1.5 µg) was injected into the subphase of 
these monolayers, and the adsorption of PLTP to the interface was monitored by the 
change in surface pressure (Δπ) (Figure 8 and II, Fig. 1). The binding of HA-PLTP to 
the lipid-­‐buffer interface decreased linearly with increasing π0 (II, Fig. 1); linear 
extrapolation of the π0-­‐Δπ?curve indicated that HA-PLTP could not penetrate the PL 
monolayer surface at π0 >25 mN/m. At higher π0 values, no changes in surface 
pressure were detected. Similar results were obtained when using LA-PLTP, except 
that the critical surface penetration pressure was estimated to be 33 mN/m (II, Fig. 1). 
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teflon coated plate
Surface
pressure
 
                                 
 Figure 8. Illustration of a monolayer system. Monolayers are monomolecular lipid 
membranes spread on air buffer  interface. In this system surface pressure is 
monitored with a Wilhelmy wire attached to a microbalance.Proteins can be injected 
to the subphase and their penetration into lipid membrane is monitored by the 
increase in surface pressure. 
 
5.2.2 PLTP is capable of transferring phospholipids from a 
monolayer 
To study whether PLTP can cause desorption of PL from the fluid monolayer and 
transfer it to the aqueous subphase, [14C]DPPC monolayers were prepared.  
The initial surface pressure for these monolayers was 7 ± 0.5 mN/m. After a 3 h 
incubation following the addition of either LA-PLTP or HA-PLTP, the radioactivity 
recovered in the subphase had increased almost 7-fold as compared to that observed 
for the control monolayers (II, Fig. 2). 
 
PLTP mass in the subphase was analyzed using the ELISA method. From the added 
total HA-PLTP, 10.3 % (134 ng) was in the subphase; i.e., 90 % of the HA-PLTP was 
associated with the lipid monolayer. Analogously, 11.0 % (167 ng) of LA-PLTP was 
found in the subphase, and therefore 89.0% is bound on the monolayer. From the 
added HDL (119 µg), equal amounts were recovered in the lipid monolayer and in the 
subphase (II). 
 
The amount of total desorbed DPPC-associated radioactivity in the subphase was 
4.2% without any added proteins. After 3 h of incubation with LA-PLTP, 26.4% of the 
total radioactivity was encountered in the subphase, whereas in the presence of HA-
PLTP and HDL3, 27.6% and 38%, respectively, were found in the subphase. In the 
presence of both LA-PLTP or HA-PLTP and HDL3, 35.2% and 39.5%, respectively, 
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were found in the subphase (II, Fig. 2). The measured radioactivities of collected 
subphases clearly demonstrated the lipoprotein enhanced transfer of DPPC from the 
PL monolayer. 
 
Estimation of the stoichiometry and the specific activity of DPPC/PLTP binding from 
the subphase indicated that on average, 5.5 mol of DPPC/mol of PLTP was desorbed 
to the subphase. Accordingly, in addition to the two defined lipid-binding pockets, 
more lipid molecules are attached to the surface of PLTP in accordance with previous 
results (Nishida and Nishida, 1997). 
 
5.2.3 Studies of PLTP–mediated phospholipid transfer using asymmetrical 
flow field-flow fractionation method 
Flow field-flow fractionation was firstly used for the separation and fractionation of 
HA-PLTP, HDL3, small unilamellar vesicles (SUVs), and their mixtures. The 
components were efficiently separated, and the diameter of HA-PLTP appeared to be 
∼ 6 nm, that of HDL3 ∼?8 nm, and that of SUVs ∼?25 nm (II, Fig. 3A). Discoidal 
reconstituted apoA-I-­‐phospholipid-­‐cholesterol particles were resolved into three peaks 
due	   to the formation of three discoidal subgroups (II, Fig. 3B), which have	   also 
previously been detected by native gradient gel electrophoresis (Matz et al., 1982; 
Jänis et al., 2005). 
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                       Figure 9. Principle of flow field-flow fractionation method. 
 
 
To clarify the mechanism whereby PLTP facilitates lipid transfer, radioactively 
labeled ([14C]DPPC) egg PC-­‐SUVs and HDL3 were incubated in the presence of either 
HA-PLTP (activity 10 µmol/mL/h) or LA-PLTP (activity 10 nmol/mL/h). Mixtures 
were subjected to AsFlFFF analysis before and after 45 min incubation. 
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Before incubation, at time 0 min, radioactive phospholipids were almost exclusively 
associated with the SUVs. During the 45 min incubation, approximately 30% of the 
radioactivity was transferred to a position corresponding to HDL3 particles (II, Fig. 
4A). This transfer only occurs in the presence of HA-PLTP, while the inactive form, 
LA-PLTP, does not mediate the transfer of phospholipids (II, Fig. 4B). Incubation of 
SUVs and HDL3 in the absence of LA- or HA-PLTP did not cause any transfer of 
SUV-associated radioactivity. The size of the different particles remained unaltered 
(II, Fig. 4). 
 
In order to record the distribution of PLTP among the different particles (either SUVs, 
HDL3 or unbound PLTP) during the phospholipid transfer process, [35S]-labeled HA- 
and LA-PLTP were used. At the start, time point 0 min, both forms of [35S]PLTP were 
associated with the same fractions as the SUVs (II Fig. 4C,D). However, after a 45 
min incubation, a marked transfer (approximately 26 %) of the radioactively labeled 
[35S]-HA-PLTP to the HDL3 position was detected (II, Fig. 4C). No such transfer of 
radioactively labeled [35S]-LA-PLTP was observed (II, Fig. 4D). These results 
demonstrate that while HA-PLTP has the ability to attach to and detach from lipid 
environments and transfer lipids to HDL3, while LA-PLTP is unable to carry out the 
transfer function. 
 
To determine the ability of discoidal apoA-I-­‐phospholipid and apoA-I-­‐phospholipid-­‐
cholesterol particles to receive lipids from PLTP molecules, these particles were 
incubated with [14C]DPPC containing SUV donors. After incubation for 45 min and 
following AsFlFFF analysis, no transfer of radioactivity was detected in any of our 
experiments (II, Fig. 5). The data indicate that these disc-shaped apoA-I particles do 
not act as acceptors in phospholipid transfer processes as mediated by active PLTP. 
  
5.3 PLTP is secreted from the lacrimal gland 
Sections of isolated lacrimal glands were immunohistochemically stained with 
monoclonal antibodies to PLTP (Mab 59). The staining patterns were similar for all 
nine lacrimal glands studied. The basal cells of intra-glandular ducts gave a positive, 
granular staining pattern. Accumulation of secreted PLTP was also seen in the lumen 
(III, Fig. 1). Yet, corneal epithelial cells also show strong PLTP immunoreactivity 
(unpublished data). 
 
 
5.4 PLTP-protein interactions in tear fluid 
To study possible protein-protein interactions of PLTP in TF, heparin affinity 
chromatography was used to separate PLTP from the TF. Following two consecutive 
heparin-Sepharose (H-S) affinity separations fractions containing active PLTP were 
collected and separated on SDS-PAGE gels mass spectrometry. Immunoblotting using 
Mab59 confirmed the presence of PLTP in the SDS-PAGE gels. Coomassie staining 
of the SDS-PAGE gel displayed several bands. The bands were excised and subjected 
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to MALDI-TOF analysis. Subsequent database searches showed significant hits for 
lactotransferrin, lactoperoxidase, proline-rich protein 1, and lysozyme C (III, Table 
1). In addition, lipocalin-1 and serum amyloid A were detected in some samples. All 
of these proteins have previously been detected in TF and may represent protein-
protein interaction partners to PLTP. However, it is also possible that these proteins 
appear in the PLTP fraction due to a direct interaction with the immobilized heparin. 
 
5.4.1 PLTP does not interact with lysozyme-C, lactoperoxidase, 
lipocalin, or serum amyloid A 
Coimmunoprecipitation and Western blotting were used to investigate the interaction 
of PLTP with the proteins coeluted in H-S chromatography and identified by MALDI-
TOF mass spectrometry. Yet, after several immunoprecipitation experiments both 
with and without detergent (0.1 % Triton X-100), no unambiguous binding was 
observed between lipocalin or serum amyloid A. A very weak band for lysozyme and 
lactoperoxidase was observed and these protein pairs (i.e., PLTP-lysozyme and PLTP-
lactoperoxidase) were further analyzed by direct binding assays.  
PLTP and lysozyme or PLTP and lactoperoxidase (2 µg of each protein) were 
incubated and subjected to PLTP pull-down assay. The results clearly demonstrated 
that direct binding was not evident. (III) Although direct binding between PLTP and 
the two proteins could not be observed, an interesting observation was that incubation 
of PLTP with lysozyme reduced the binding of PLTP to the H-S column, suggesting 
some degree of masking of the heparin-binding domain of PLTP protein.  
 5.4.2 PLTP forms a complex with human tear fluid mucins  
Interaction of PLTP with human TF mucins was studied using a PLTP 
immunoprecipitation assay. Mucin was not detectable in mass spectrometry analysis 
because ocular mucin did not enter the 12.5 % SDS-PAGE gel due to its high apparent 
molecular weight (about 220 kDa). Fifty microliters of human TF was incubated with 
polyclonal anti-PLTP antibody (R 290; 1 mg) in the presence of protein G. The 
immunoprecipitate was collected and analyzed by Western blotting using monoclonal 
antibodies against PLTP and mucin. The results suggested an interaction between 
PLTP and ocular mucins (III, Fig. 3). 
 
Many studies have used commercially available mucins as substitutes for ocular 
mucins such as BSM. Prompted by the finding that active PLTP interacted with ocular 
mucins in human TF, interaction with purified BSM and non-mammalian ovomucin 
were studied using a dot-blot analysis. The results demonstrated that purified active 
PLTP was directly bound in a concentration-dependent manner to BSM, whereas 
ovomucin failed to interact with active PLTP (III, Fig. 4). 
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5.4.3 Characterization of the mucin–PLTP interaction 
Possible functional implications for mucin-PLTP interaction in TF were elucidated 
through an in vitro experiment. First, a phospholipidation protocol was used to 
generate a BSM/ovomucin-phospholipid (phosphatidylcholine, PC) complex. The 
complex, which also contained a trace amount of 14[C]-DPPC, was incubated together 
with purified PLTP. SEC was used to investigate the PLTP distribution. SEC elution 
profiles of the mucin-PC-PLTP samples in PBS or in PBS-Tween 20 can be seen in 
original paper (III, Fig. 5.)  
When elution was performed with PBS, PLTP coeluted with BSM-PC in a broad 
range. BSM, [14C]-DPPC, cold PC, and PLTP coeluted in same fraction, suggesting a 
complex formation between these components. When an addition of 0.05 % Tween 20 
was used in the elution PBS buffer, PLTP was released from the complex with mucins 
(both BSM and OVM) and it eluted around the apparent molecular weight of 160 kDa. 
 
In SEC analysis, lipidated ovomucin elutes in two major peaks and PLTP elutes in 
three peaks, while two of these PLTP peaks mirror the ovomucin ones. The coelution 
of ovomucin, PLTP, and radiolabeled phospholipids in the same fractions suggests 
that the lipidated ovomucin can form a complex with PLTP. PLTP does not interact 
with ovomucin in the absence of phospholipids, and therefore sticks non-specifically 
to the column matrix (III, Fig 5.). 
 
5.5 PLTP knock-out increases dry eye symptoms in mice 
PLTP KO mice were used to study whether the lack of endogenous PLTP induces 
ocular changes. These findings were compared to the experimentally induced dry eye 
(EIDE) model presented by Dursun et al (2002). 
   
5.5.1 PLTP is present in plasma and in tear fluid in wild-type mice  
High immunoreactivity for PLTP was seen in the plasma of WT mice but was totally 
absent in the plasma of PLTP KO mice. Pooled TF samples of three eyes derived from 
both the normal and PLTP KO groups were analyzed by Western blot using the 
monoclonal anti-PLTP (MAb 59) antibody. Wild-type C57 Black mice showed a faint 
immunoreactivity (due to low yield of mouse tear fluid) at the apparent molecular 
weight of ~80 kDa, the predicted molecular weight of PLTP (IV). 
 
5.5.2 Corneal histology of PLTP KO mice shows dry eye changes 
Corneal histology was investigated in four groups of mice: WT or PLTP KO mice, 
and similar mice in which dry eye was induced experimentally (EIDE). The PLTP KO 
and EIDE WT and PLTP KO mice showed mild wing cell irregularity and some 
epithelial blebs compared to WT mice without EIDE. Compared to PLTP KO mice, 
both types of EIDE mice presented with more severe corneal alterations and 
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hyperkeratization (IV, Fig. 1 and 2). During the study period, a total of 253 PLTP KO 
mice were housed in our laboratory. In this group, six (2.4 %) spontaneous 
perforations were observed, while in the same period of time, WT C57black mice 
(n=631) had no corneal perforations. 
 
5.5.3 Corneal epithelial permeability is increased in PLTP KO mice 
Increased corneal epithelial permeability to fluorescein dye is a characteristic 
finding for dry eye (Göbbels and Spitznas, 1989). Corneal epithelial 
permeability to carboxyfluorescein (CF) (molecular weight 750 Da) was 
assessed in WT, PLTP KO, and EIDE WT and PLTP KO mice. Compared to 
WT mice, permeability to CF was significantly increased in PLTP KO mice, as 
well as in EIDE WT / PLTP KO mice groups (IV, Fig. 4), suggesting a role for 
PLTP in corneal epithelial homeostasis. Mice (on a C57BL/6 backround) that 
are homozygous null for the PLTP gene are viable, fertile, normal in size and 
do not display any gross physical or behavioral abnormalities. No PLTP 
mRNA is detected in the tissues that normally express PLTP (lung, liver). No 
plasma PLTP activity is detected (Jiang et al., 1999).   
 
5.5.4 PLTP KO mice have decreased expression of the tight junction 
protein occludin 
The normal cornea barrier function is maintained by tight junctions in the 
differentiated apical corneal epithelial cells. Increased occludin cleavage has been 
reported in dry eye (Pflugfelder et al., 2005). The corneal endothelium showed strong 
immunoreactivity with the polyclonal occludin antibody and this immunoreactivity 
was used to normalize occludin expression in the epithelium. That is, epithelial 
immunoreactivity was compared to endothelial immunoreactivity, which was 
considered to be constant in all the studied mouse groups.  
In WT mice, occludin protein expression was seen in the endothelium, as well as in 
the epithelium, but not in the corneal stroma (IV, Fig. 5A). The expression pattern for 
occludin in PLTP KO mice was significantly different: The endothelium showed 
bright immunofluorescence but epithelial expression was significantly reduced (IV, 
Fig. 5B). Both types of EIDE mice showed decreased epithelial occludin protein 
expression (Fig. 5C&D). Quantitation of epithelial occludin protein expression 
confirmed these findings and showed a significantly decreased expression of occludin 
in PLTP KO mice, as well as in EIDE PLTP KO mice, compared to WT mice 
(p<0.05) (IV, Fig. 5). Although epithelial occludin expression was lower in EIDE WT 
mice compared to WT mice, this difference was not significant (p=0.11). 
 
5.5.5 PLTP KO mice show normal histology of eyelids 
In several dry eye knockout models, like ACAT-1 null (ACAT-1-/-) mice, the dry eye 
symptoms arise from the atrophy of the palpebral glands (Yagyu et al., 2000). To 
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verify that the observed dry eye induction was not caused by atrophy of the 
Meibomian glands, we examined the histology of WT and PLTP KO mouse eyelids. 
The histological analysis of PLTP KO mouse eyelids was normal and the histology of 
Meibomian glands was similar to those in WT mice (IV, Fig. 6). 
 
5.6 PLTP activity in human tears correlates to hyperosmolarity 
Tear osmolarity is considered to be the most accurate single test to show dry eye 
(Tomlinson et al., 2006); a tear osmolarity level over 316 mOsm/kg is considered to 
show dry eye. A preliminary study was done to examine the relationship between 
human TF osmolarity and PLTP activity. Increased TF PLTP activity associates 
significantly with tear hyperosmolarity (> 316 mOsm/kg) (IV, Fig 7).    
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6 DISCUSSION 
6.1 PLTP is a component of normal tear fluid 
One of the main outcomes of this thesis project was to demonstrate that human TF 
displays phospholipid transfer activity. PLTP activity, as well as immunodetectaable 
PLTP protein, was demonstrated in all human and WT mouse tear samples. Western 
blot using the monoclonal anti-PLTP antibody (Mab 59) of human and mouse TF 
samples displayed a single 80 kDa band corresponding to the predicted molecular 
weight of the mature, highly glycosylated form of human PLTP. Inhibiting PLTP by 
heat treatment or by a polyclonal anti-PLTP antibody resulted in almost total 
inhibition of PLTP activity in tears. These results suggest firmly that PLTP is a normal 
component of TF. 
 
A recent analysis (Li et al., 2005) of the protein composition of human TF revealed 
only 54 proteins that were identified with high confidence. In this study, Li et al. also 
confirmed the presence of PLTP in TF. Yet, de Souza and collaborators (2006) were 
able to identify nearly 500 proteins in human TF using multiple mass spectrometric 
approaches. It seems that in the latter study, however, the authors may have had 
significant contaminants from the ocular tissues. This is evidenced by the relatively 
large number of intracellular proteins, as well as the fact that not all of the major 
proteins, such as phospholipases, were found. The relatively small amount of 
identified proteins in the study of Li et al. (2005) suggests a high stature for these key 
proteins in human TF. As the composition and functional regulation of TF remains 
largely unknown, it is important to characterize the factors that play a role in the 
homeostatic processes of TF such as the organization of lipids and viscoelasticity of 
the tear film. 
 
6.2 PLTP is secreted from the lacrimal gland 
In this thesis study, no correlation between tear and plasma PLTP concentration, 
activity, or specific activity was observed, and thus it is likely that TF PLTP does not 
originate from the circulation. The secretion route of PLTP to the TF was studied 
through the immunostaining of tissue samples of ocular origin. The PLTP was found 
to be secreted from lacrimal glands. Yet, also the corneal epithelium is likely to 
contribute to the TF PLTP concentration (unpublished data). The immunostaining 
pattern with a specific monoclonal antibody against PLTP in the lacrimal gland 
sections was very similar to that already demonstrated for another members of lipid 
transfer/lipopolysaccharide binding protein family (Peuravuori et al., 2006), and also 
to that of TF lipocalin (Glasgow, 1995). PLTP expression in the other ocular surface 
tissues is not presented in this study, but it seems that at least some degree of 
expression of PLTP is found in these tissues. The lacrimal gland serves as a 
predominant source of TF proteins, and thus it is likely that this is the main source of 
TF PLTP. 
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6.3 CETP and human tear fluid 
CETP is a member of the lipid transfer/lipopolysaccharide binding protein family that 
also includes PLTP, LBP, and BPI. Of these, the BPI is a lacrimal gland–derived 
normal component of TF, while PLTP and CETP play an important role in plasma 
lipoprotein metabolism. The major function of CETP in plasma is to facilitate the 
transfer of cholesteryl esters from HDL to apolipoprotein B–containing lipoproteins 
and the reciprocal transfer of triglycerides (Tall et al., 1983). 
 
In the present work, cholesteryl ester transfer activity was not detected in TF. A 
possible explanation for the absence of CETP in tear fluid may be that CETP cannot 
reach cholesteryl esters/triglycerides in the superficial lipid layer, or that there is no 
need for such lipid transfer activity. The superficial tear film is composed of 2–3 lipid 
layers. Phospholipids and other amphiphilic molecules are located next to the aqueous 
interface because of the hydrophobic effect (Tanford, 1980; Kulovesi et al., 2010). 
Externally to this, cholesteryl esters/triglycerides are located on a more disordered 
manner in 1–2 layers, depending on the surface pressure (Rantamäki et al., in press). 
Accordingly, phospholipids cause a steric obstruction for CETP or other neutral lipid 
transferring proteins to reach their ligands. Thus, there is no reason that these neutral 
lipids should be transported to the superficial lipid layer. The evidence for the 
presence of cholesterol esters and triglycerides in TF derives from chemical analysis 
of the composition of the Meibomian gland excretions (McCulley and Shine, 1997), 
which certainly differs from the actual lipid layer resting on the top of the tear fluid. In 
this thesis the lipid composition of the TF was analyzed with enzymatic assays. The 
majority of the lipids were phospholipids, whereas the concentration of cholesterol 
and neutral lipids was below the detection limit of the enzymatic assays (unpublished 
data). This scenario would provide a very convenient explanation for the lack of 
cholesteryl ester transfer activity in TF and would necessitate a revision of the 
arrangement of the superficial tear film lipid layer. 
 
6.4 PLTP activity in tear fluid 
In human plasma, PLTP exists in two different forms, one with high activity (HA) and 
the other with low activity (LA) (Oka et al., 2000). In the plasma of mice 
overexpressing human PLTP, these two different populations of PLTP have also been 
observed (Jaari et al., 2001). Catalytically active plasma PLTP can be separated from 
the catalytically low-activity form by SEC or by using the heparin-binding properties 
of the active PLTP (Kärkkäinen et al., 2002). In SEC, PLTP activity has been 
demonstrated to elute with an average mass of 160 kDa, whereas the inactive form of 
PLTP has been shown to elute in a position corresponding to a molecular size of 520 
kDa (Oka et al., 2000). In this study, human TF-derived PLTP displayed 
characteristics very similar to the HA form in human plasma. PLTP was quantitatively 
bound on an H-S column and PLTP activity and PLTP protein comigrated in a 
position corresponding to the apparent molecular mass of 160–170 kDa during SEC. 
Catalytically inactive PLTP was not observed in any of the studied fractions. These 
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findings suggest that the TF compartment lacks the molecular machinery that 
facilitates the generation of the LA form of PLTP observed in plasma.  
 
Only one gene has been reported to code for both forms of the human PLTP protein, 
indicating that PLTP activity regulation occurs at the posttranslational level (Tu et al., 
1995).  It remains to be established whether the two forms of PLTP possess different 
functions in plasma or if LA-PLTP is just a remnant of HA-PLTP. The binding of LA- 
and HA-PLTP to lipids needs to be studied and may give a clue as to whether lipid 
composition is related to the activity of PLTP in tear fluid. The finding that the 
specific activity of tear PLTP was lower compared to plasma implicates that enzyme 
activity could be differently regulated. It may be that the proteins have different sets of 
oligosaccharide structures, and their different specific activities might possibly reflect 
these variations. Another possibility for the difference in specific activity is that the 
activity of plasma PLTP is partly regulated by protein-protein interactions, that are 
different in TF. 
 
6.5 PLTP activity and apolipoproteins in tear fluid 
In plasma, an active PLTP has been demonstrated to coelute with apoE but not with 
apoA-I or apoB-100, while the low-activity form of PLTP associates with apoA-I 
(Kärkkäinen et al., 2002). The activity could be inhibited only with antibodies against 
PLTP or apoE (McCulley and Shine, 1997). These findings suggest an in vivo 
selectivity of the PLTP interaction between apolipoproteins. As a first step to 
identifying the proteins with which tear PLTP might associate, the presence of apoA-I 
and apoE in tear fluid were analyzed. Neither apoA-I nor apoE were found in TF, 
suggesting that the observed lowered specific activity of TF PLTP might reflect the 
absence of these proteins. 
 
During the normal PLTP purification process from plasma, the final purified PLTP 
protein does not contain any other copurified proteins, and is nevertheless highly 
active (Jauhiainen et al., 1993). This is further supported by the observations that 
human PLTP produced in the baculovirus protein expression system (Siggins et al., 
2004), as well as PLTP in human seminal plasma (Masson et al., 2003), are fully 
active but that neither contain apoA-I nor apoE. An explanation for this may be that as 
PLTP binds phospholipids, it is able to maintain the active conformation. This concept 
is supported by the finding that purified plasma PLTP indeed interacts with several 
phospholipid molecules (Nishida and Nishida, 1997). These observations might 
suggest a possible different physiological function of PLTP in TF compared to 
plasma. It remains possible that in TF, no protein will be found associated with PLTP 
and that PLTP is still catalytically active.  
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6.6 PLTP-protein interactions in tear fluid 
To elucidate possible PLTP-protein interactions in TF, specific immunoprecipitation 
and binding assays were carried out. The heparin-bound active PLTP fractions were 
analyzed by MALDI-TOF mass spectrometry, which revealed several candidate 
proteins (lactoperoxidase, lactotransferrin, proline-rich protein 1, lysozyme C, 
apolipoprotein J [clusterin], serum amyloid A, and lachryglobin). Of these proteins, 
apolipoprotein J and serum amyloid A, as well as PLTP and lipocalin, are known to 
interact avidly with phospholipids (Jenne et al., 1991; Bausserman et al., 1983). Thus, 
complex formation between these proteins seems to be physiologically reasonable. 
Yet, further analysis using Western blotting could not confirm binding of any of these 
proteins to PLTP.  
Lysozyme and lactotransferrin are major TF proteins and thus most likely represent 
contaminants in the sensitive MALDI-TOF analysis. The results of binding assays 
with purified proteins clearly demonstrated that direct binding was not evident. 
Although direct binding between PLTP and the two proteins could not be observed, an 
interesting observation was that incubation of PLTP with lysozyme reduced the 
binding of PLTP to the H-S column (data not shown), suggesting some degree of 
masking of the heparin-binding domain of PLTP protein or that lysozyme might 
compete with PLTP for heparin binding sites in the column.  
As PLTP does not show interaction with either of the proteins studied here, it seems 
likely that in TF, no other proteins are needed to maintain the PLTP capability of 
transferring phospholipids. As TF does not contain apoA-I or apoE, which seem to 
regulate the activity in plasma, it seems a plausible explanation that PLTP avidly binds 
phospholipids from TF and this phospholipidated form alone could maintain the active 
molecular conformation. 
 
6.7 PLTP in an air-water environment 
Lipid monolayers residing on an air-buffer interface provide a convenient means to 
mimic lipid transfer processes in TF, where the outermost layer consists of lipids. In 
this study, a series of monolayer experiments were performed to explore the surface 
properties of PLTP. To act efficiently in TF, a protein must be surface active; this was 
experimentally verified for both HA- and LA-PLTP (II, Fig. 1). HA-PLTP binds to 
monolayers with a critical surface penetration pressure of around 25 mN/m. This is 
somewhat lower than the 29–34 mN/m range of other plasma apolipoproteins and 
CETP (Weinberg et al., 1994), while the critical surface penetration pressure of LA-
PLTP was estimated to be 33 mN/m LA-PLTP (II, Fig 1).  
This may be important for the more efficient release of HA-PLTP from the 
hydrophobic environment compared to other apolipoproteins and LA-PLTP, which 
may be more strongly docked to the phospholipid monolayer surface of lipoprotein 
particles. The very stable tertiary structure and relatively low surface exclusion 
pressure of HA-PLTP suggest that, when bound to the monolayer interface, HA-PLTP 
does not unfold like many other apolipoproteins. Furthermore, it may be that HA-
PLTP does not penetrate deeply into the fatty acyl chain region of the lipid layer but 
mainly resides at the headgroup level. This is in accordance with the proposed shuttle 
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mechanism of PLTP, in which PLTP should be able to efficiently attach to and detach 
from the donor and acceptor particles. 
 
In monolayer studies, both HA- and LA-PLTP were able to absorb lipid molecules 
from the monolayer (II, Fig. 2). The calculated stoichiometry of one PLTP molecule 
to desorb 5–6 molecules of DPPC is within the same range when compared to earlier 
estimations of the unspecific phospholipid binding of the PLTP molecule outside the 
N-terminal pocket (Nishida and Nishida, 1997). This unspecific binding explains why 
LA-PLTP is also able to absorb phospholipids from the phospholipid monolayer.  
An increased absorption was seen when HA-PLTP was combined with HDL3 
molecules (II, Fig. 2). This may indicate that, after absorbing lipids from the lipid 
monolayer, PLTP attaches to the HDL3 particle where it can release bound lipids. 
Another mechanism is that HDL3 can directly absorb lipids from the lipid monolayer, 
which seems more likely since LA-PLTP and HDL3 mixtures also show increased 
subphase radioactivity. 
  
6.8 PLTP and mucins in tear fluid 
Ocular mucins are thought to be located at the surface of the tear film, where they 
cause an increase in surface pressure by generating lateral reorganization of the lipids 
and alteration of surface viscoelastic properties (Millar et al., 2006). The 
contamination of ocular surface mucins with lipids from the superficial lipid layer can 
lead to drying of the corneal epithelium (Holly and Lemp, 1971). This can happen 
when the aqueous-mucin layer becomes too thin or the lipid contaminates the mucin 
layer. A lipid saturation of the corneal epithelium forms a hydrophobic area that 
prevents wetting of the surface above it, leading to the formation of DES. Thus, a 
mechanism to prevent contamination and remove lipids from the ocular surface is 
necessary. 
 
Immunoprecipitation assay suggested that PLTP directly interacts with ocular mucins 
in human TF (III, Fig. 3). These findings were confirmed by series of further studies 
to characterize the PLTP-mucin interactions. The collection of human ocular mucins 
in volumes for in vitro interaction experiments is challenging, and thus in many 
previous studies, commercially available mucins have been used as substitutes for 
ocular mucins such as BSM and avian-derived ovomucin. While each human mucin 
gene has a unique tandem repeat amino acid sequence, length, and variation in allele 
number of repetitions among individuals (Mantelli et al., 2008), it is reasonable to 
consider that BSM and ovomucin are an adequate model for tear mucins during in 
vitro experiments. In vitro a direct binding assay showed that PLTP avidly interacts 
with BSM, but not with avian-derived ovomucin. A possible explanation for this is 
that there are some structural differences between these proteins (Lang et al., 2006). 
The ß-subunit of ovomucin, which is an avian ortholog to a secreted human mucin 
(MUC6), has an unusual organization, as the tandem repeats of the STP domain are 
encoded by multiple exons where each exon encodes one repeat (Lang et al., 2006). 
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Mucin-lipid-PLTP interactions were studied in more detail with SEC, where a PLTP- 
mediated transfer of radioactively labeled phospholipids from phospholipidated mucin 
was registered. The SEC analysis showed that phospholipids can act as interaction 
partners between mucin and PLTP or to promote the interplay between the two 
proteins. When PLTP was incubated with the phospholipidated mucin, PLTP eluted 
together with mucin in fractions corresponding to a wide molecular size range. 
Detergent in the buffer significantly changed the PLTP elution profile, as well as that 
of phospholipids, indicating a disruption of the mucin-PLTP interaction. It has been 
shown that mucin proteins have hydrophobic regions that can bind lipids (Smith et al., 
1984). PLTP can function as a phospholipid transfer protein both in the presence of 
apolipoproteins such as apoAI and apoAII or alone when directly bound to 
phospholipids. The displacement of phospholipids and PLTP from phospholipidated 
mucin by detergent encourages the consideration that phospholipids play a key role in 
the mucin-PLTP interaction. The broad elution profile of mucin in PBS could be 
explained by the size heterogeneity of the gel-forming mucin. The wide heterogeneity 
of mucin molecules was also noted by preliminary AsFIFFF experiments, where 
mucin complexes were observed with a hydrodynamic diameter ranging from 25 up to 
225 nm (data not shown). 
 
 
6.9 PLTP and phospholipid transfer mechanism 
Lipids can be exchanged and transferred between different lipoprotein classes by 
spontaneous, temperature-dependent transfer or by protein-mediated transfer (Tall, 
1995). In plasma, protein-mediated transfer of lipids is facilitated by CETP and PLTP. 
Two different models of PLTP-mediated lipid transfer have been proposed: (i) a 
shuttle model in which PLTP physically transports lipids between lipoprotein particles 
and (ii) a ternary complex model in which PLTP forms a bridge between two 
lipoprotein particles, enabling them to exchange lipids by diffusion (Tall, 1995; Barter 
et al., 1994). On the basis of kinetic evidence, it has been suggested that CETP 
facilitates lipid transport by a shuttle mechanism between HDL  and acceptor 
lipoprotein particles like VLDL and LDL (Barter and Jones, 1980; Epps et al., 1995). 
In favor of the shuttle model, it has also been demonstrated that CETP can absorb 
lipids from phospholipid monolayers residing at the air-water interface (Weinberg et 
al., 1994).   
 
To supplement the monolayer studies where PLTP was able to absorb lipids from air-
water interface, and to elucidate the actual lipid transfer mechanism of PLTP in more 
detail, a series of flow field-flow fractionation studies were done. With this method, 
the lipid components were more efficiently separated and their sizes were more 
homogeneous than previously described (Li and Giddings, 1996). In addition, 
reconstituted apoA-I-phospholipid-cholesterol particles were resolved in three peaks 
due to the formation of three discoidal subgroups, which have also previously been 
detected by native gradient gel electrophoresis.  
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With AsFIFFF studies, the transfer of radiolabeled lipids from SUVs to HDL3 
following the addition of HA-PLTP, but not LA-PLTP, was noted. The particle size of 
HDL3 was not altered in either experiment, suggesting that no ternary complexes were 
formed. In addition, the radiolabeled HA-PLTP and LA-PLTP molecules showed that 
after incubation, the active PLTP itself was transferred from SUVs to HDL3. These 
results strongly suggest that the shuttle mechanism like in the use of CETP (Epps et 
al., 1995) is the preferred mechanism of PLTP-induced lipid transfer.  
 
In the monolayer series, both LA- and HA-PLTP showed lipid-binding capability in 
water-air interface, but LA-PLTP was unable to deliver lipids to the acceptor particle 
in AsFIFFF studies. These results suggest that even if the surface of LA-PLTP can 
unspecifically bind lipids, the complex cannot dock on the acceptor. Similar results 
were seen when the structure of the acceptor particles was changed. Both apoA-I-
phospholipid discoidal and apoA-I-phospholipid cholesterol particles were unable to 
receive lipids from PLTP. In AsFIFFF assay where SUVs and HDL3 are used as 
substrates for PLTP, the curvature of the SUV and HDL3 may be an important 
determinant for the activity of PLTP. On a monolayer where lipids are resting on the 
surface of the buffer, they display a very small degree of curvature, while SUVs and 
especially HDL3 have a high degree of curvature. Within these molecules, a surface 
layer distortion is needed for the formation of sufficient gaps that may accommodate 
the interfacial binding site of HA-PLTP and proper interaction of the active site with 
the phospholipid to be transferred. It seems that because LA-PLTP is unable to adopt 
an active conformation, proper interactions between SUV and HDL3 are hindered. 
 
 
 
6.10 PLTP–deficient mice and dry eye 
To study the effect of PLTP deficiency on the homeostasis of eye, a KO mouse model 
was used. This model was compared to the dry eye mouse model (EIDE) described by 
Dursun et al. (2002), where TF production is attenuated by the cholinergic blockade 
with scopolamine. Compared to the cholinergic blockade, the PLTP KO mice showed 
similar morphological changes in the cornea. In addition, increased corneal 
permeability and cleavage of epithelial occludin were noted in these mice. During the 
follow-up time, 2.4% of PLTP KO mice suffered spontaneous perforation of an eye, 
while the WT animals grown under the same conditions had no eye problems. 
 
PLTP KO mice were also treated with scopolamine to see whether the effects are 
additive. PLTP KO with EIDE did not further induce corneal permeability or occludin 
cleavage. Presumably, these two models can separately cause a maximal permeability 
to CF with the concentrations used. The activation of matrix metalloproteases, 
especially MMP-9, that are primarily responsible for occludin cleavage in corneal 
epithelium (Pflugfelder et al., 2005) seems to be involved in both PLTP KO and EIDE 
treatment. 
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Several animal models that mimic human dry eye have been introduced. Most of these 
models resemble autoimmune disease seen in human Sjögren syndrome, since the key 
factor in the formation of DES is diminished aqueous tear production. 
As the tear lipid film imbalance and the evaporative DES are common diseases of the 
eye, an experimental model that mimics this condition is needed. In addition, at the 
moment the techniques used to diminish the production of TF in different animal 
models mostly alter the presence of ocular surface system. Mechanical cauterization of 
Meibomian gland orifices (Gilbard et al., 1989) and other lid surgery techniques, as 
well as mutant and transgenic techniques to induce aplasia or atrophy, heavily change 
the function of the normal ocular surface structure even before formation of DES. In 
addition, the animal model of blepharitis (Chan et al., 1995) itself induces ocular 
surface irritation and alters the immunological profile of the ocular surface, which is 
an important factor in the development of DES. 
Among PLTP KO mice, TF production was similar to that recorded in WT littermates. 
In addition, the eyelid and Meibomian gland morphologies were normal in PLTP KO 
mice. It seems that the imbalance of TF is a key element in the development of DES in 
these mice, and thus the PLTP knockout model serves as a relevant model of human 
evaporative DES.  
 
 
6.11 PLTP as a scavenger of the ocular surface 
Tear lipocalin, a common tear lipoprotein, has been proposed to serve as a scavenger 
of lipophilic substances from the corneal surface (Glasgow et al., 1999). Even though 
lipids can be extracted from Tlc and it seems to be capable of binding lipids (Gasymov 
et al., 2005), it has been discussed whether Tlc can actually bind to lipid membranes 
and accept membrane lipids (Saaren-Seppälä et al., 2005). 
Tear PLTP has lipid transfer ability without any acceptor molecule and is active 
without any detectable protein-protein associations (I). In contrast to Tlc, which binds 
lipids at a 1:1 protein/lipid ratio (Glasgow et al., 1999), PLTP can accommodate up to 
43 mol of phosphatidylcholine and 13 mol of cholesterol with one mol of PLTP 
(Nishida and Nishida, 1997). A high number of PLTP-bound lipids are seen even 
though only two specific lipid binding pockets have been identified in PLTP 
(Huuskonen et al., 1999). These pockets might only be needed for specific lipid 
transfer of this protein and the rest of the associated phospholipids may be needed for 
proper folding of the protein and stabilizing the enzymatic activity.  
 
Human lung tissue, where PLTP is found at air-water atmosphere, displays high levels 
of PLTP compared to other tissues. In the lung, PLTP may serve an important role in 
maintaining the normal function of this organ, such as in the transport of surfactant 
components, primarily phospholipids. The PLTP gene is highly expressed in alveolar 
type II cells, and is induced during hypoxia and in emphysema (Jiang et al., 1998), 
indicating important surface protective properties. A somewhat analogous situation to 
emphysematous lungs might be what takes place in DES. More specifically, the 
superficial lipid layer provides a barrier to prevent evaporation of TF that would 
eventually lead to pathological damage of the corneal epithelium. In TF, PLTP could 
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facilitate the uptake of Meibomian lipids and ultimately transport them to the 
superficial lipid layer. Likewise, if the corneal epithelium were contaminated by 
hydrophobic material, PLTP could scavenge these and transport them to the 
superficial layer of the TF or, alternatively, scavenge lipids by binding them and 
transporting them through the naso-lacrimal duct. PLTP might play an integral role in 
tear lipid trafficking and in the protection of the corneal epithelium.  
 
In line with these findings, human DES patients show significantly elevated levels of 
PLTP activity in tears, suggesting an induction of PLTP activity under hyperosmolar 
conditions (IV). 
 
The results of this thesis do not contradict the previous findings, which propose that 
Tlc is the key lipid transfer molecule and a scavenger of TF lipids (Glasgow et al., 
2010). However, it seems unreasonable to assume that only one protein would be 
solely responsible for removing ocular contaminants in the TF. The homolog of 
human Tlc is von Ebner’s gland protein (VEGP) in rats (Kock et al., 1994), Can f1 in 
dogs (Konieczny et al., 1997), and in pigs (Garibotti et al., 1995), a homologous 
protein, pVEG, is produced by the lacrimal glands. Like in humans, there is more than 
one gene encoding for rat VEGP (Kock et al., 1994). However, in contrast to humans, 
where only one form of Tlc was found to be expressed, in rats three different closely 
related proteins have been found to be expressed (Syed et al., 1999). It is interesting to 
note that in mice, cows, and guinea pigs, no homologous protein to Tlc has been 
detected so far, either by immunohistochemical methods or by hybridization. Thus, it 
seems that during evolution, several different scavenger proteins of TF have arisen 
and in humans it seems reasonable that PLTP acts together with Tlc to maintain a 
normal ocular surface.  
 
Together, these findings suggest a notable role of PLTP in lipid transfer in human 
tears. PLTP could play a significant role in preventing instability of the lipid film and 
thus reduce the development of DES. The precise mechanisms of tear PLTP-facilitated 
phospholipid transfer and its association with different ocular structures remain to be 
clarified in the future.  
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7 SUMMARY AND CONCLUSIONS 
The aim of this thesis was to verify the presence of PLTP in human tear fluid, 
investigate lipid transfer mechanisms in tear fluid, and evaluate the possible association 
of PLTP in dry eye.   
 
First, the presence of the high-activity form of PLTP was demonstrated by Western blot 
in all human tear samples studied. Also tear fluid derived from the wild-type mice 
displayed immunoreactive PLTP. Inhibition of PLTP with heat treatment or by 
polyclonal anti-PLTP antibody resulted in the almost total inhibition of phospholipid 
transfer activity in tears. The secretion route of tear PLTP was demonstrated via 
immunostaining of tissue samples of ocular origin. PLTP was found to be secreted 
from lacrimal glands. These results suggest firmly that PLTP is a normal component of 
TF. 
 
To characterize the role of PLTP in the lipid transport in an air-water interface, several 
monolayer and AsFlFFF lipid transfer assays were performed. PLTP seems to be 
surface active and is capable of accepting lipid molecules without the presence of lipid-
protein complexes. The active movement of radioactively labeled lipid and HA-PLTP 
to acceptor particles suggested a shuttle model of PLTP-mediated lipid transfer. In this 
model, PLTP physically transports lipids between the donor and acceptor. In light of 
these results, a shuttle model is more evident than a ternary complex model, in which 
PLTP forms a bridge between two lipoprotein particles.  
 
To further characterize the molecular mechanisms of PLTP-mediated lipid transfer in 
TF, the association of PLTP with TF proteins was elucidated. Apolipoproteins 
responsible for PLTP activity in serum were found to be absent in TF. PLTP was also 
able to transfer lipids without any associated protein partners. The only proteins 
interacting with PLTP in human TF were mucins. These results suggest a scavenger 
property of TF PLTP: If the corneal epithelium is contaminated by hydrophobic 
material, PLTP could remove it and transport it to the superficial layer of the TF or, 
alternatively, abolish lipids by binding them and transporting them through the naso-
lacrimal duct. Thus, PLTP might play an integral role in tear lipid trafficking and in the 
protection of the corneal epithelium. 
 
To reveal whether the results obtained in vitro bear any relevance in vivo, a mouse 
model with a selective deficiency in PLTP was used. In these mice, enhanced corneal 
epithelial damage, increased corneal permeability, decreased corneal epithelial occludin 
expression, and even perforations of the eye were detected. These findings were similar 
to those of previous dry eye models and correlate to observations in human dry eye. As 
the imbalance of TF is a remarkable cause of human DES, it seems that PLTP lipid 
transfer is needed to maintain the normal function of TF and a healthy ocular surface. 
Results represented in this thesis indicate that the mouse PLTP KO model serves as a 
relevant model of evaporative DES.  
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To study whether PLTP plays a role in human DES, a series of DES patients were 
examined. Tear osmolarity is found to be the single most efficient indicator of DES. In 
this study, a significant correlation between elevated osmolarity and increased PLTP 
activity was shown. 
  
At the time being, lipocalin is thought to be responsible for the lipid transfer in human 
TF. However, it seems unreasonable to assume that only one protein would be solely 
responsible for removing ocular contaminants in the TF. The results of this thesis 
suggest that although PLTP is a minor constituent of normal TF, it possesses efficient 
phospholipid transfer activity, and thus it is likely that PLTP aids Tlc, and perhaps 
other proteins, to decontaminate the ocular surface. These results suggest that in the TF, 
PLTP may act in concert with human tear lipocalin to ensure efficient lipid transfer. 
The specific mechanism of PLTP in lipid transfer processes in tears and the detailed 
lipid composition of TF will be important targets to investigate in order to define the 
exact role of PLTP in DES. 
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